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A B S T R A C T
Background
Current guidelines recommend oral anticoagulation therapy for patients with atrial fibrillation who are at moderate-to-high risk of
stroke, however anticoagulation control (time in therapeutic range (TTR)) is dependent on many factors. Educational and behavioural
interventions may impact on patients’ ability to maintain their International Normalised Ratio (INR) control.
Objectives
To evaluate the effects on TTR of educational and behavioural interventions for oral anticoagulation therapy (OAT) in patients with
atrial fibrillation (AF).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects
(DARE) in The Cochrane Library (2012, Issue 7 of 12), MEDLINE Ovid (1950 to week 4 July 2012), EMBASE Classic + EMBASE
Ovid (1947 to Week 31 2012), PsycINFO Ovid (1806 to 2012 week 5 July) on 8 August 2012 and CINAHL Plus with Full Text
EBSCO (to August 2012) on 9 August 2012. We applied no language restrictions.
Selection criteria
The primary outcome analysed was TTR. Secondary outcomes included decision conflict (patient’s uncertainty in making health-
related decisions), percentage of INRs in the therapeutic range, major bleeding, stroke and thromboembolic events, patient knowledge,
patient satisfaction, quality of life (QoL), and anxiety.
Data collection and analysis
The two review authors independently extracted data. Where insufficient data were present to conduct a meta-analysis, effect sizes and
confidence intervals (CIs) of the included studies were reported. Data were pooled for two outcomes, TTR and decision conflict.
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Main results
Eight trials with a total of 1215 AF patients (number of AF participants included in the individual trials ranging from 14 to 434) were
included within the review. Studies included education, decision aids, and self-monitoring plus education.
For the primary outcome of TTR, data for the AF participants in two self-monitoring plus education trials were pooled and did not
favour self-monitoring plus education or usual care in improving TTR, with a mean difference of 6.31 (95% CI -5.63 to 18.25). For
the secondary outcome of decision conflict, data from two decision aid trials favoured usual care over the decision aid in terms of
reducing decision conflict, with a mean difference of -0.1 (95% CI -0.2 to -0.02).
Authors’ conclusions
This review demonstrated that there is insufficient evidence to draw definitive conclusions regarding the impact of educational or
behavioural interventions on TTR in AF patients receivingOAT. Thus, more trials are needed to examine the impact of interventions on
anticoagulation control in AF patients and the mechanisms by which they are successful. It is also important to explore the psychological
implications for patients suffering from this long-term chronic condition.
P L A I N L A N G U A G E S U M M A R Y
Educational and behavioural interventions to increase the time in the therapeutic range for patients with atrial fibrillation on
anticoagulant therapy
Atrial fibrillation is a chronic condition that is characterised by an irregular heart beat. This irregularity of the heart rhythm places
people with atrial fibrillation at greater risk of forming blood clots and subsequently increases their risk of stroke. The most common
treatment for reducing the risk of stroke is medication with oral drugs that ’thin’ the blood, known as oral anticoagulants, to reduce
the risk of blood clots forming. People taking warfarin are regularly monitored to assess the time it takes for their blood to clot,
known as the International Normalised Ratio (INR), to ensure that the INR is within the target therapeutic range of 2.0 to 3.0. This
narrow therapeutic range is often difficult to achieve due to the many factors that can affect INR control such as alcohol intake, other
medications, and food intake.
Educational and behavioural interventions may play an important role in improving the ability of people with atrial fibrillation to
maintain their INR control, by increasing their knowledge and understanding about warfarin and atrial fibrillation. The objectives
of this review were to assess the effects of educational and behavioural interventions for people with atrial fibrillation who were on
warfarin to maintain a therapeutic INR range.
Eight studies were finally included within the review. Interventions included patient education, decision aids, and self-monitoring plus
education. The primary outcome for the review was the percentage of time the INR was within the therapeutic range. Decision conflict,
measuring patients’ uncertainty in making health related decisions and factors contributing to that uncertainty, was also a common
outcome for decision aid trials. Other outcomes included the percentage of INRs in the therapeutic range, major bleeding, stroke,
thromboembolic (clotting) events, knowledge, patient satisfaction, quality of life, and anxiety.
Three self-monitoring plus education trials reported the time in the therapeutic range; the pooled data did not favour either self-
monitoring or usual care.Data from twodecision aid trials favoured usual care in terms of reducing people’s decision conflict surrounding
treatment uptake and adherence.
The review authors concluded that more trials are needed to examine the impact of educational and behavioural interventions on
anticoagulation control in people with atrial fibrillation. We now have novel oral anticoagulants that do not require monitoring of
INR as warfarin does. Education is particularly important to provide safety information and ensure patients are able to make informed
decisions about treatment options and to manage their oral anticoagulation therapy. However, more disease-specific theory-driven
interventions need to be trialled to understand the mechanisms by which such interventions can be successful.
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B A C K G R O U N D
Description of the condition
Atrial fibrillation (AF) is the most common arrhythmia in clini-
cal practice (Fuster 2006). The lifetime risk of developing AF is
approximately one in four among people aged 40 years or older
(Lloyd-Jones 2007). The incidence and prevalence of AF is rising.
OneUS population-based study (n = 4618) found the age and sex-
adjusted incidence of AF per 1000 person-years was 3.04 (95%CI
2.78 to 3.31) in 1980, increasing to 3.68 (95% CI 3.42 to 3.95)
in 2000; amounting to a relative increase of 12.6% (Miyasaka
2006). Similar findings in the European Rotterdam Study (n =
6806) found that the overall prevalence of AF was 5.5% to 6.0%
in men and 5.1% in women (Heeringa 2006). The prevalence of
AF dramatically increases with age, rising from 0.5% at 40 to 50
years of age to 5% to 15% at 80 years (Go 2001; Heeringa 2006;
Lloyd-Jones 2004;Miyasaka 2006; Stewart 2001), with the preva-
lence being slightly higher in men than in women (Lloyd-Jones
2004). AF is associated with a five-fold greater risk of stroke and
thromboembolism (Wolf 1991), and the incidence of stroke at-
tributable to AF also increases with age (Lip 2006). When includ-
ing hospital admissions, treatment costs, and long-term nursing
home care, AF accounts for 0.62% of the total UK healthcare ex-
penditure, with a projected cost of 0.88% of the total expendi-
ture in 2000 (Stewart 2004). Given the increasing incidence and
prevalence of AF these figures are likely to rise.
Patients with an increased risk of stroke (as determined by stroke
risk stratification models) should receive long-term oral anticoag-
ulant therapy (OAT), unless contraindicated. In a meta-analysis,
dose-adjusted OAT, within the International Normalized Ratio
(INR) range of 2.0 to 3.0, significantly reduced the risk of is-
chaemic stroke or thromboembolism in patients with non-valvu-
lar AF by 39% (95% CI 22% to 52%) and 64% (95% CI 41% to
62%), respectively, compared with both either aspirin or placebo
(Hart 2007). Whilst OAT dramatically reduces stroke risk, the
therapeutic range of the INR is narrow and must be maintained.
This can be problematic, with INRs greater than 3.0 increasing the
risk of major and minor bleeding and INRs less than 2.0 increas-
ing the risk of thromboembolism (Lip 2006). Regular INR mon-
itoring is essential and patients need to carefully adhere to dietary
and lifestyle restrictions (Ansell 2004). A retrospective analysis of
OAT in the UK demonstrated that only patients with the greatest
INR control increased their time to stroke occurrence, with only
patients spending over 71% of their time in the target therapeutic
range (TTR) benefiting (Morgan 2009). In practice, 51% of pa-
tients at high risk of stroke (CHADS2 score 2 or more) remained
outside of the target therapeutic range for at least 50% of the time
(Morgan 2009). Further, a post hoc analysis of patients enrolled
in the ’Atrial Fibrillation Clopidogrel Trial With Irbesartan for
Prevention of Vascular Events’ (ACTIVE), which randomised AF
patients with one additional stroke risk factor to receive clopido-
grel 75 mg/d plus aspirin (75 to 100 mg/d recommended dose)
or OAT, found that patients with a TTR less than 58% gained no
benefit fromOAT. The INRmust be within the therapeutic range
for at least 58% of the time to confer benefit in terms of stroke
risk reduction (Connolly 2008). Thus, maintenance of INR is a
major concern for both AF patients and healthcare professionals.
Furthermore, whilst interventions targeting this patient group ul-
timately aim to reduce the risk of stroke, patients’ TTR is a good
short-term indicator of whether the patients will experience ad-
verse events in the long-term, thus presenting a useful trial end-
point.
The inherent difficulties associated with warfarin (narrow thera-
peutic range; drug, alcohol, and food interactions; regular blood
tests) have led to the development of novel oral anticoagulant
drugs, which have sought to overcome these problems by providing
an efficacious and safe alternative treatment that does not require
regular monitoring. Several new oral anticoagulant drugs have
been tested in clinical trials, some of which have been completed
(Connolly 2009;Connolly 2011;Granger 2011; Patel 2011)while
others (Ruff 2010) are still ongoing. Whilst the use of novel an-
tithrombotics may shift the focus of interventions for this patient
group, it is important investigate ways in which we can improve
the outcomes of patients still taking warfarin and whether the
principles used for interventions with this group are also relevant
for the new oral anticoagulants.
Given that AF is a chronic condition that places patients at in-
creased risk of mortality and morbidity, particularly from stroke,
and often requires life-long treatment, including long-term OAT,
the educational materials and the support given to patients when
they are first prescribed OAT are crucial for the maintenance of
their treatment regimens.
Description of the intervention
Attempts to support behaviour change can take numerous forms.
At the individual level they almost always fall into the category
of ’education or communication’ and may use one or more be-
haviour change techniques (NICE 2007). Patient education for
OAT has attempted to influence patient behaviour and improve
knowledge, attitudes, and practices that are necessary to improve
health outcomes (Wofford 2008). Techniques used in delivering
patient education cover a wide spectrum, including the use of
booklets and videos as media to transmit additional information
either alone or in addition to self-management interventions (such
as INR self-monitoring) and interventions which use decision
aids (Khan 2004a; Man-Son-Hing 1999). Patient knowledge sur-
rounding OAT varies with age (Tang 2003). Elderly patients (> 75
years) demonstrate poorer knowledge. In one study less than half
of one patient sample were able to name even one specific benefit,
risk, or lifestyle change associated with warfarin (Coehlo-Dantas
2004). In several cases spouses were more knowledgeable than the
patients and appeared to play a vital role in monitoring the indi-
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vidual’s treatment regime (Coehlo-Dantas 2004). Therefore, edu-
cational interventions for this particular patient group may prove
to be particularly beneficial.
Other interventions focus on behavioural and practical aspects
of lifestyle change and treatment. Behavioural interventions aim
to modify patients’ behaviour towards treatment and symptoms
(NICE 2007). Interventions that use these principles to promote
change include cognitive behavioural therapy (CBT), motiva-
tional interviewing, and heart rate variability biofeedback. CBT
is a goal-oriented, systematic procedure which aims to solve prob-
lems concerning dysfunctional emotions, behaviours, and cogni-
tions and to promote positive attitude, self efficacy, and planning.
However, with any complex intervention it is difficult to deter-
mine which component has influenced the behavioural outcome.
Interventions vary in duration and levels of support. Clearly it is
important for trials to be explicit about the content and delivery of
their interventions and to choose appropriate evaluation tools in
order to examine how and why their interventions are successful.
How the intervention might work
Interventions for patients with AF who receive OAT should ulti-
mately aim to improve clinical outcomes, primarily reducing the
prevalence of stroke and mortality. However, in the short-term we
can aim to increase patients’ time in the therapeutic range (TTR)
by focusing on factors that affect treatment adherence. Many fac-
tors can affect INR control, such as drug-drug interactions and
variable dietary vitamin K intake (Holbrook 2005), but with ad-
equate knowledge surrounding treatment and lifestyle factors in-
terventions should aim to encourage behaviour change through
education. It has been suggested that several factors influence ad-
herence, and these factors are either intentional or unintentional.
Intentional non-adherence can occur when patients make a deci-
sion not to take their treatment as a result of their personal moti-
vations or beliefs, or both. Unintentional non-adherence refers to
an individual’s skills or ability to take his or her medications (for
example problems with remembering to take tablets).
Based on the literature surrounding patient adherence, poor INR
control could result from both unintentional and intentional non-
adherence.Where patients’ knowledge of their condition and their
OAT is limited, this may impact on their practical ability to man-
age treatment (unintentional) and their perceptions surround-
ing treatment necessity (intentional). Several studies have demon-
strated that patients have poor knowledge of AF and its treatment
(Lane 2006; Lip 2002; Nadar 2003; Tang 2003). There is evi-
dence that patient knowledge correlates significantly with TTR
(Tang 2003), with more knowledgable patients having a greater
TTR. Thus by improving patient knowledge of factors affecting
their TTR and how to manage OAT treatment, patients may be
more able to adhere to the treatment regimen. In clinical terms,
if education can demonstrate an improvement in TTR, it could
have important clinical benefits (that is the reduction of adverse
events such as stroke and major bleeding). Decision aids are infor-
mative interventions designed to help peoplemake specific choices
surrounding their medications, and they may also increase patient
knowledge. These interventions aim to reduce decision conflict,
which refers to the patient’s uncertainty in making health-related
decisions and the factors relating to that uncertainty, which may
subsequently impact on treatment uptake and adherence.
Intentional non-adherence may be more difficult to target and
interventions need to focus on inaccurate perceptions of medica-
tions. The common sense model (Leventhal 1992) suggests that
patients hold beliefs about the necessity of their prescribed med-
ication (Specific-Necessity) and concerns about prescribed med-
ication based on beliefs about the danger of dependence and
long-term toxicity as well as the disruptive effects of the medica-
tion (Specific-Concerns). The model also describes general beliefs
about medication, assessing beliefs that medicines are addictive
and harmful (General-Harm) and that medicines are over-pre-
scribed by doctors (General-Overuse). These beliefs, and the way
in which patients balance their concern about medications, have
been widely used in predicting medication adherence in a vari-
ety of chronic conditions including rheumatoid arthritis (Neame
2005), asthma (Jessop 2003), type II diabetes (Farmer 2006), and
depression (Aikens 2005).
A comparison of beliefs about medications between adherent,
unintentional non-adherent, and intentionally non-adherent pa-
tients found significant differences in medication-related beliefs
in patients with a range of chronic illnesses after being newly pre-
scribedmedication for the last 10 days (Clifford 2008). Compared
with adherers, intentional non-adherers had significantly lower
scores on the necessity subscale of the Beliefs about Medication
Questionnaire (P value 0.012), higher scores on the concerns sub-
scale (P value 0.008), and lower scores on the necessity-concerns
differential (P value 0.001). There were no significant differences
between adherers andunintentional non-adherers (Clifford 2008).
Evidently, whilst unintentional non-adherers may benefit from
memory aids (that is reminders, tablet dosettes), intentional non-
adherers may need to address both their perceptions of their med-
ication and misinformation, which may be achieved by increasing
patient education surrounding their treatment. Intentional non-
adherers appear to doubt their personal need for their medication
and have concerns about taking it when compared to adherers.
Thus focusing on the necessity of warfarin for stroke risk reduc-
tion and alleviating concerns surrounding warfarin treatment may
change inaccurate perceptions and potentially lead to increased
patient adherence.
Why it is important to do this review
AF is a condition that is increasing in prevalence (Miyasaka 2006)
and requires treatment with OAT to reduce associated stroke risk.
However, patients on warfarin need to to maintain a narrow ther-
apeutic INR range, which may be difficult to achieve in practice
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(Morgan 2009). Patients need sufficient information to make in-
formed choices and actively participate in themanagement of their
own treatment (Thrall 2004). Patient education aims to influence
patient behaviour and improve knowledge, attitudes, and practices
that are necessary to improve health outcomes (Wofford 2008),
but the efficacy of patient interventions designed to improve AF
patient adherence toOAT is not clear. By increasingpatient knowl-
edge and understanding surrounding AF and OAT we may re-
duce the prevalence of intentional and unintentional non-adher-
ence, subsequently increasing TTR. TTR is important and has
been shown to be a predictor of thromboembolic or haemorrhagic
complications, although it is a surrogate for the hard endpoints
such as reductions in mortality and stroke that OAT is aimed at
achieving. TTR does give an indication as to whether patients are
adhering tomedication, which should translate into a reduction in
stroke and major bleeding events. This review evaluated the value
of educational and behavioural interventions for patients with AF
who were currently prescribed warfarin, including the impact on
TTR and secondary outcomes such as decision conflict, patient
knowledge, and quality of life.
O B J E C T I V E S
To evaluate the effects on TTR of educational and behavioural
interventions for oral anticoagulation therapy (OAT) in patients
with atrial fibrillation (AF).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of educational or behavioural
interventions with any length of follow-up and in any language
were included.
Types of participants
Adults (aged 18 years or older) with AF, categorised according to
the European Society of Cardiology (ESC) guidelines (ESC 2010),
including:
• newly diagnosed AF,
• paroxysmal AF, defined as episodes that usually terminate
spontaneously (usually in less than 48 hours), but may last for up
to seven days,
• persistent AF, characterised by an episode lasting more than
seven days or requiring termination via cardioversion,
• long-standing persistent AF, where AF has been present for
> one year (i.e. permanent AF) but where a rhythm control
strategy is adopted,
• permanent AF, where AF has been continuous for more
than one year and accepted as the ’normal’ heart rhythm by the
patient and the physician (hence no rhythm control adopted).
AF was diagnosed and documented by electrocardiogram (12-lead
or Holter monitoring). Patients that were eligible for, or currently
receiving, OAT were considered for inclusion in this review. Stud-
ies which included AFpatients with othermedical conditions were
also included in this review. The studies were RCTs comparing
at least one intervention with a control group, and including pa-
tients with AF as either the study population or a specified sub-
group. Studies were only included where patients were grouped
per indication, that is for patients taking oral anticoagulants for
AF, deep vein thrombosis or pulmonary embolism (DVT or PE),
valve replacements etc, only AF patient data were included within
the analysis.
Types of interventions
All types of educational and behavioural interventions given to AF
patients who were taking OATwere considered for this systematic
review. Educational interventions included those that delivered
patient information, such as:
• educational booklets;
• videos as media to transmit additional information;
• self-management interventions (such as INR self-
monitoring) that also educated patients;
• decision aids;
• talking interventions.
Behavioural interventions included techniques that attempted to
modify patients’ behaviour towards treatment and symptoms, such
as:
• cognitive behavioural therapy (CBT);
• self-monitoring or management interventions that include
significant educational components;
• motivational interviewing;
• heart rate variability biofeedback.
Interventions could target adults on the individual level or as a
group. The intervention may have taken place in the emergency
department, a hospital, the home, or in the community and could
have been delivered by a nurse, pharmacist, educator, health or
medical practitioner, or a multidisciplinary team associated with
the hospital or referred to by the hospital. The intervention could
have been undertaken at any time point from diagnosis of AF or
initiation of OAT (that is not only newly diagnosed AF patients
or those newly referred for anticoagulant therapy). Trials were
only considered where the comparison groups were usual care,
no intervention, or the intervention in combination with other
self-management techniques. Usual care was defined as standard
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anticoagulation clinic practice, where patients attended routine
INR checks (defined as usual care by the author). Any length of
follow-up was included. We have endeavoured to ensure that our
review is clearly distinct from the Garcia-Alamino 2010 review.
In particular, we have only included self-monitoring interventions
where they include a clear and distinct educational component
(in addition to training on the use of the self-monitoring device);
this should include topics in addition to self-testing, such as risk
information, lifestyle changes, and information pertaining to their
condition.
Types of outcome measures
Primary outcomes
The primary outcome measure was the percentage of time spent
within the therapeutic range (TTR), as defined by Rosendaal and
colleagues (Rosendaal 1993) (INR 2.0 to 3.0).
Secondary outcomes
The secondary outcomes were:
• major bleeding (defined as bleeds that result in death, are
life threatening, cause chronic sequelae, or consume major
healthcare resources) and minor bleeding (Schulman 2004);
• stroke and thromboembolic events;
• increased knowledge with regard to AF and anticoagulation
therapy;
• patient satisfaction;
• acceptability of the anticoagulant therapy;
• quality of life; psychological well-being;
• changes in perception towards AF and INR control;
• changes in the patients’ illness beliefs and illness
representations;
• self-reported adherence to treatment and a change in the
patients’ beliefs about medications;
• economic costs of the intervention (cost-effectiveness);
• decision conflict*.
*Decision conflict was included as a secondary outcome in the
final analysis. Whilst not specified as an outcome of interest in
the original protocol, it was highlighted as a common secondary
outcome measure in three of the studies included in the final
review. For this reason, the authors decided to include these data
within the results.
These outcomes were quantified using validated or non-validated
questionnaires, ratings, or scales.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) and the Database of Abstracts of Reviews of Effects
(DARE) inThe Cochrane Library (2012, Issue 7of 12),MEDLINE
Ovid (1950 to week 4 July 2012), EMBASE Classic + EMBASE
Ovid (1947 to Week 31 2012), PsycINFO Ovid (1806 to week 5
July 2012) on 8 August 2012 and CINAHL Plus with Full TEXT
EBSCO (to August 2012) on 9 August 2012. See Appendix 1 for
the search strategies.
Searching other resources
Abstract books from national and international cardiology, psy-
chology, and psychiatry conferences were handsearched, to include
meetings relating to AF and meetings that discussed the develop-
ment of educational and behaviour change interventions, includ-
ing:
• European Society of Cardiology;
• American College of Cardiology;
• American Heart Association;
• Society for Behavioural Medicine and the Division of
Health Psychology Conference;
• European Health Psychology Conference;
• Royal College of Psychiatrists Annual Meeting.
Dissertation abstracts (UMI ProQuest Digital Dissertations) were
also searched. Reference lists of all relevant papers were searched
to identify other potentially relevant articles.
No language restrictions were applied to the searches.
Data collection and analysis
Selection of studies
Two authors (Clarkesmith and Lane) independently scrutinised
the titles found from the search and decided on inclusion or ex-
clusion. From the included titles these two authors (Clarkesmith
and Lane) then independently selected the abstracts and papers
for inclusion and exclusion. We used Cohen’s kappa statistic to
assess agreement between the two authors on the selection of arti-
cles for inclusion. At the first review stage (June 2010), the kappa
coefficient was 98.4%. Following the updated search in 2012, the
kappa coefficient was 95%. Where disagreements arose the full-
text article was accessed to determine whether the study met the
inclusion and exclusion criteria. The authors discussed the article
and agreement was reached by consensus.
Data extraction and management
Two review authors independently extracted the data. For each
trial, the following data were extracted (where available) using a
specially designed data extraction form: participants (sample size,
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age, sex, ethnicity, marital status, type of AF); type of anticoag-
ulation therapy (warfarin, other); type and duration of the inter-
ventions (intervention versus usual care or no intervention, other
combinations); primary (TTR) and secondary outcomes (increase
in knowledge with regard to AF and anticoagulation therapy, de-
cision conflict, time within the therapeutic INR range, patient
satisfaction, acceptability of the anticoagulant therapy, quality of
life, changes in perception towards AF and INR control, changes
in the patients’ illness beliefs and illness representations, changes
in the patients’ beliefs about medications, self-reported adherence,
psychological well-being); length of follow-up; statistical methods
employed; the effect size and its precision. Studies were included
in this review if they reported any of the primary or secondary out-
comes of interest, regardless of whether the original study’s primary
or secondary outcomes corresponded with the review’s primary or
secondary outcomes. For example, if a study reported TTR as a
secondary outcome the TTR was included in this review but as
the primary outcome.
Assessment of risk of bias in included studies
Two review authors independently assessed the methodological
quality of each trial in accordance with guidance in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Each study was assessed in several areas of bias (sequence genera-
tion, allocation concealment, degree of blinding particularly of the
outcome assessors, patient attrition rate, selective reporting bias).
The risk of bias was determined using the Cochrane Collabora-
tion’s risk of bias tool.
We asked if the domains listed below were considered to be ade-
quate. There were three possible responses: low risk, high risk, or
unclear risk. The criteria for responses are outlined below.
Sequence generation
• Low risk, if the allocation sequence was generated using
techniques such as a random number table; a computer random
number generator; coin tossing; shuffling cards or envelopes;
throwing dice; or cluster randomisation.
• High risk, if the allocation sequence was generated using
techniques such as odd or even date of birth; date (or day) of
admission; hospital or clinic record number.
• Unclear risk, if there was insufficient information about the
sequence generation process to permit judgement.
Allocation concealment
• Low risk, if the allocation concealment used methods such
as central allocation (including telephone, web-based, and
pharmacy-controlled randomisation); sequentially numbered
drug containers of identical appearance; sequentially numbered
opaque, sealed envelopes.
• High risk, if the participants or investigators enrolling
participants could possibly foresee assignments and thus
introduce selection bias, such as allocation based on using an
open random allocation schedule (e.g. a list of random
numbers); assignment envelopes used without appropriate
safeguards (e.g. if envelopes were unsealed or non-opaque, or not
sequentially numbered); alternation or rotation; date of birth;
case record number.
• Unclear risk, if there was insufficient information to permit
judgement of ’Yes’ or ’No’. If the method of concealment was
not described or not described in sufficient detail to allow a
definite judgement (e.g. if the use of assignment envelopes was
described but it remained unclear whether envelopes were
sequentially numbered, opaque and sealed).
Where the method of allocation was unclear, we contacted study
authors to provide further details.
Blinding
• Low risk, if there was no blinding but the review authors
judged that the outcome and the outcome measurement were
not likely to be influenced by lack of blinding; if blinding of
participants and key study personnel was ensured and it was
unlikely that the blinding could have been broken; if either
participants or some key study personnel were not blinded but
outcome assessment was blinded and the non-blinding of others
was unlikely to introduce bias.
• High risk, if there was no blinding or incomplete blinding
and the outcome or outcome measurement was likely to be
influenced by lack of blinding; if blinding of key study
participants and personnel was attempted but it was likely that
the blinding could have been broken; if either participants or
some key study personnel were not blinded and the non-
blinding of others was likely to introduce bias.
• Unclear risk, if there was insufficient information to permit
judgement of ’Yes’ or ’No’ or the study did not address this
outcome (e.g. where the blinding was described only as double-
blind without any other details).
Incomplete data assessment (loss of participants, for
example with withdrawals, dropouts, protocol deviations)
• Low risk, if there were no missing outcome data; reasons for
missing outcome data were unlikely to be related to the true
outcome; missing outcome data were balanced in numbers across
intervention groups with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of
missing outcomes compared with observed event risk was not
enough to have a clinically relevant impact on the intervention
effect estimate; for continuous outcome data, plausible effect size
(difference in means or standardised difference in means) among
missing outcomes was not enough to have a clinically relevant
impact on observed effect size; missing data were imputed using
appropriate methods; for cluster randomised trials, an error
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made in statistical analysis when the analysis does not take
account of the unit of allocation. In some studies, the unit of
allocation is not a person but is instead a group of people.
Sometimes the data from these studies are analysed as if people
had been allocated individually. Using individuals as the unit of
analysis when groups of people are allocated can result in overly
narrow confidence intervals. Thus, where included in meta-
analysis, it can result in studies receiving more weight than is
appropriate and this must be accounted for.
• High risk, if the reasons for missing outcome data were
likely to be related to true outcome, with either imbalance in
numbers or reasons for missing data across intervention groups;
for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk was enough to
introduce clinically relevant bias in the intervention effect
estimate; for continuous outcome data, plausible effect size
(difference in means or standardised difference in means) among
missing outcomes was enough to introduce clinically relevant
bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that
assigned at randomisation; potentially inappropriate application
of simple imputation.
• Unclear risk, if there was insufficient reporting of attrition
or exclusions to permit judgement of ’Yes’ or ’No’ (e.g. numbers
randomised were not stated, no reasons for missing data were
provided); or the study did not address this.
Selective outcome reporting
• Low risk, if the study protocol was available and all of the
study’s pre-specified (primary and secondary) outcomes that were
of interest in the review were reported in the pre-specified way;
the study protocol was not available, but it was clear that the
published reports included all expected outcomes including
those that were pre-specified.
• High risk, if not all of the study’s pre-specified primary
outcomes were reported; one or more primary outcomes were
reported using measurements, analysis methods, or subsets of the
data (e.g. subscales) that were not pre-specified; one or more
reported primary outcomes were not pre-specified (unless clear
justification for their reporting was provided, such as an
unexpected adverse effect); one or more outcomes of interest in
the review were reported incompletely so that they could not be
entered in a meta-analysis; the study report failed to include
results for a key outcome that would be expected to have been
reported for such a study.
• Unclear risk, if there was insufficient information to permit
judgement of ’Yes’ or ’No’.
Other sources of bias
• Yes, if the study appeared to be free of other sources of bias.
• No, if there was at least one important risk of bias (e.g. the
study had a potential source of bias related to the specific study
design used; stopped early due to some data-dependent process
(including a formal stopping rule); had extreme baseline
imbalance; had been claimed to be fraudulent; had some other
problem).
• Unclear, if there was either insufficient information to assess
whether an important risk of bias existed or if there was
insufficient rationale or evidence that an identified problem
would not introduce bias.
Measures of treatment effect
Statistical analyses were undertaken as follows. For continuous
variables (for example changes in illness perception questionnaire
or changes in TTR), the weighted mean difference was used. As
a summary measure of effectiveness, odds ratios with 95% confi-
dence intervals (CIs) were calculated for dichotomous variables.
Dealing with missing data
Where the article indicated inclusion of AF patients, but data was
not included by subgroup, we contacted the authors of the in-
cluded studies to gather AF-specific data. We also contacted au-
thors where there was insufficient detail on the demographic data
for AF patients or the content of the intervention. We received
responses and additional data from several authors (Beyth 2000;
Christensen 2007; Gadisseur 2003; Polek 2012; Thomson 2007).
For nine studies the authors could not be contacted (Sawicki 1999;
Stone 1989; Watzke 2000) or did not respond to e-mail or writ-
ten requests for unpublished data (Barcellona 2006; Chan 2006;
Gardiner 2006;Menendez-Jandula 2005; Ryan 2009; Siebenhofer
2007). For one study (Machtinger 2007) the author was success-
fully contacted but the data were unavailable. If authors responded
with data that were incomplete they were contacted again for fur-
ther details.
Assessment of heterogeneity
Assessment of heterogeneity of studies included in themeta-analy-
sis were carried out using the I2 statistic, to describe the proportion
of the variability in the results not due to chance. Whilst there was
no significant heterogeneity between the studies included in the
meta-analysis, the studies varied substantially in their intervention
design and cohort demographics, thus a random-effects statistical
model was adopted for the analysis. In addition, the Chi2 test for
heterogeneity was performed and the data were considered het-
erogenous if the P value was less than 0.10.
Assessment of reporting biases
There were not enough studies in this review to test for reporting
bias, thus the findings were discussed as a narrative review. How-
ever, future revisions will test for bias using a funnel plot based on
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the data for the primary outcome of time spent within therapeutic
INR range (TTR). Asymmetry of the funnel plot will be taken as
an indication of publication bias. Other causes of asymmetry of
the funnel plot will also be looked at, such as clinical heterogene-
ity between studies (for example different control event rates) or
methodological heterogeneity between studies (for example fail-
ure to conceal allocation). A summary of who was blinded during
both the conduct and analysis of the study was summarised in a
narrative review and the conclusions informed the risk of bias tool.
The completeness of the data was summarised and any concerns
over the exclusion of participants or excessive dropouts were re-
ported. Concerns over the selective reporting of outcomes, time
points, or subgroups were also reported.
Data synthesis
Results of individual studies were combined within a narrative re-
view. Where possible and appropriate, meta-analysis was used to
statistically combine results. TTR data were included if directly
reported using the Rosendaal method (Rosendaal 1993) of calcu-
lation or where available from personal communication with the
authors. For the analysis we used Review Manager (Version 5.1).
For the statistical analysis we calculated mean differences and 95%
CIs as the summary statistics. We examined heterogeneity using
the Chi2 and the I2 statistics (Higgins 2011). We used a random-
effects model to calculate a pooled mean difference where signifi-
cant heterogeneity existed between studies.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were carried out looking at the type of inter-
vention (educational alone, behavioural alone, and a combination
of education and behavioural versus usual care). Future revisions
may also examine frequency (one session versus multiple sessions)
and duration (less than sixmonths versusmore than sixmonths) of
the intervention, length of time on OAC, men versus women, in-
dividual versus group interventions, and age of participant groups
dependant upon the availability of such data in the included study
reports.
Sensitivity analysis
There were insufficient studies to carry out sensitivity analyses.
However, future revisions of the review may employ sensitivity
analyses to examine factors that may lead to differences between
the results of individual trials: poor quality versus good quality
trials.
R E S U L T S
Description of studies
Results of the search
The search retrieved 1040 de-duplicated articles from all sources.
Of these, 954 were excluded by assessing the titles and abstracts.
We obtained 86 full-text articles for consideration. Seventy articles
were excluded based on the review of the full-text article. Three
studies were included as ongoing trials. Thirteen articles reporting
on eight studies were included in the final review.
Included studies
Thirteen articles reporting on eight studies were included in this
review (Beyth 2000; Christensen 2007; Gadisseur 2003; Man-
Son-Hing 1999; McAlister 2005; Polek 2012; Thomson 2007;
Voller 2005). Features of the interventions are included in the
study tables (Characteristics of included studies). See the PRISMA
flow chart for the inclusion process (Figure 1).
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Figure 1. Study flow diagram.
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Methods
All eight included studies were randomised controlled trials. Four
of the studies specifically recruited AF patients (Man-Son-Hing
1999; McAlister 2005; Thomson 2007; Voller 2005). A further
four ’mixed’ trials recruited patients with a range of indications
for OAT (for example AF, venous thromboembolism, cardiovas-
cular disease, heart valve prosthesis, peripheral vascular disease,
myocardial infarction) and provided unpublished data on the AF
patients (Beyth 2000; Christensen 2007; Gadisseur 2003; Polek
2012). One trial was a cluster randomised study (McAlister 2005)
and one (Gadisseur 2003) used a Zelen design.
Participants
The total sample size of AF patients, including published and un-
published data, varied from 14 (Polek 2012 unpublished) to 434
(McAlister 2005) participants. The mean age of the trial partici-
pants ranged from 59 to 75 years. One trial did not provide any
demographic information for their AF patients (Gadisseur 2003).
Patients were included if they had AF (McAlister 2005; Thomson
2007; Voller 2005); were receiving intravenous heparin (Beyth
2000); were aged 18 years or over (Christensen 2007; McAlister
2005), 65 years or over (Beyth 2000), 60 years or over (Thomson
2007), 18 to 75 years (Gadisseur 2003); planned to start war-
farin (Beyth 2000; Gadisseur 2003; Polek 2012; Thomson 2007);
had been taking warfarin (Thomson 2007) for > three months
(Gadisseur 2003), > eight months (Christensen 2007); were ac-
cessible via telephone (Polek 2012).
Patients were excluded if they had been treated with warfarin at
any time in the previous six months (Beyth 2000); were admitted
from a nursing home (Beyth 2000; Polek 2012); were enrolled in
another clinical trial (Beyth 2000; Voller 2005); were too ill to
give consent (Beyth 2000) or did not speak English (Beyth 2000;
McAlister 2005; Polek 2012; Thomson 2007); had previously
used self-management (Christensen 2007); had antiphospholipid
syndrome (Gadisseur 2003), a life threatening illness (Gadisseur
2003), life expectancy ≤ one year (Gadisseur 2003; McAlister
2005), cognitive impairment (Gadisseur 2003; McAlister 2005;
Polek 2012; Thomson 2007) and physical limitations making suc-
cessful participation impossible (Gadisseur 2003), poor hearing
or eyesight (Voller 2005), a major haemorrhage in a previous trial
(Man-Son-Hing 1999); were taking warfarin for another condi-
tion (McAlister 2005; Thomson 2007; Voller 2005), scheduled
for cardioversion (McAlister 2005; Thomson 2007); had a history
of psychotic disorder (Polek 2012), previous stroke or transient
ischaemic attack (TIA) (Thomson 2007), or alcohol or other ad-
diction (Voller 2005).
Types of studies
Of the eight studies that were identified, two compared educa-
tion with usual care (Gadisseur 2003; Polek 2012), four com-
pared self-monitoring plus education with usual care (Beyth 2000;
Christensen 2007; Gadisseur 2003; Voller 2005), and one also
included a self-management group (Gadisseur 2003). A further
three trials focused on the use of a decision support aid versus
usual care (Man-Son-Hing 1999; McAlister 2005) or a ’guideline
evidence’ comparison group (Thomson 2007).
Types of interventions
Interventionswere either one to one (Beyth 2000;McAlister 2005;
Polek 2012) or group training session(s) (Gadisseur 2003; Voller
2005). Three of the trials did not explicitly specify a group or
individual intervention type (Christensen 2007; Man-Son-Hing
1999; Thomson 2007).
All of the interventions included an educational element, usually
consisting of a description of the consequences of minor or major
stroke and major haemorrhage, the blood monitoring required for
warfarin, and the probability of stroke and major haemorrhage for
patients taking warfarin. Most interventions also included infor-
mation regarding the lifestyle factors influencing warfarin control.
Self-monitoring interventions included training on the use of INR
monitoring devices (Beyth 2000; Christensen 2007; Gadisseur
2003; Voller 2005).
Decision aid interventions offered more detailed information
on the risks of bleeding and thromboembolism (Man-Son-Hing
1999;McAlister 2005; Thomson 2007). All three trials using a de-
cision support aid employed pictograms to depict the risk of stroke
and bleeding on either placebo, aspirin, or warfarin; two utilised
paper-based charts (Man-Son-Hing 1999; McAlister 2005) and
the third (Thomson 2007) used a computerised version. The de-
cision aid was presented and patients were asked to select which
treatment they would prefer on the basis of the risk information
presented in the pictogram (probability trade-off technique). For
example, the consequences of a minor stroke, a major stroke, mi-
nor and major bleeding were described along with the probability
of those events occurringwhilst takingdifferent treatment options.
This gave patients the opportunity to make informed decisions
(Man-Son-Hing 1999); in this trial patients completed a work-
sheet which summarised the information following the decision
aid.
Duration of the intervention
The duration of the educational training element of the interven-
tions varied. Four trials reported a one-off consultation of 30 to
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60 minutes (Beyth 2000; Thomson 2007) or three sessions each
lasting 60 to 120 minutes (Gadisseur 2003; Voller 2005). The
other four trials did not specify how long the intervention lasted or
the number of sessions (Christensen 2007; Man-Son-Hing 1999
McAlister 2005; Polek 2012).
Intervention facilitator
Two studies did not specify the type of facilitator (Christensen
2007; Voller 2005). Of those that did, facilitators included a lay
educator (Beyth 2000); a physician, pharmacist, or healthcare pro-
fessional (Gadisseur 2003; McAlister 2005; Polek 2012); and a
computerised audio tool (Man-Son-Hing 1999; Thomson 2007).
Country
The geographical settings of the studies were: Denmark (
Christensen 2007), Netherlands (Gadisseur 2003), Germany
(Voller 2005), USA (Beyth 2000; Man-Son-Hing 1999; Polek
2012), Canada (McAlister 2005), and the UK (Thomson 2007).
Setting for the intervention
Most of the interventions were conducted in a hospital or antico-
agulation clinic setting (Beyth 2000; Christensen 2007; Gadisseur
2003; Man-Son-Hing 1999; Polek 2012). One of the trials took
place in general physician (GP) practices (McAlister 2005), an-
other in a research clinic with patients from general practices
(Thomson 2007). One of the trials did not describe the interven-
tion setting (Voller 2005).
Follow-up
Assessment of the impact of the intervention on outcomes was at
three (Polek 2012), six (Beyth 2000; Christensen 2007; Gadisseur
2003; Man-Son-Hing 1999), and 12 months (McAlister 2005;
Thomson 2007).
Funding
Three of the trials declared some funding input by drug companies
(Gadisseur 2003; Man-Son-Hing 1999; Voller 2005).
Outcome measures
Primary outcome
The percentage of time spent within the therapeutic range (TTR),
an INR of 2.0 to 3.0, was reported by three trials (Beyth 2000;
Christensen 2007; Gadisseur 2003) as outlined by the Rosendaal
method. One trial reported the TTR in days (Voller 2005). Three
trials reported other indicators of INR control: percentage of in-
range INRs (McAlister 2005; Voller 2005), and combined INR
and complications outcomes (Christensen 2007). Of those studies
reporting TTR, all tested self-monitoring plus education or edu-
cation only interventions, but only one published AF-specific data
(Voller 2005) and this trial did not use the Rosendaal method.
Thus, the remaining trial authors were contacted for AF-specific
data, which were provided by two of the authors (Christensen
2007; Gadisseur 2003). AF-specific data were not requested for
outcomes that were not comparable, that is combined INR and
complications outcomes (Christensen 2007).
Secondary outcomes
One study reported major bleeding, stroke, and thromboembolic
events and provided unpublished AF-specific data (Beyth 2000).
None of the studies reported on minor bleeding. Four trials re-
ported on patient knowledge (Man-Son-Hing 1999; McAlister
2005; Polek 2012; Thomson 2007). Two trials assessed knowl-
edge before and after the intervention (Man-Son-Hing 1999;
Thomson 2007), two only tested after the intervention (McAlister
2005; Polek 2012). Three trials included patient satisfaction
as a specified outcome (Gadisseur 2003; Man-Son-Hing 1999;
McAlister 2005). However, one trial did not report on this
outcome (McAlister 2005), thus the data were not included.
One study reported on quality of life (QoL) as an outcome
(Gadisseur 2003) using a questionnaire originally validated by
Sawicki (Sawicki 1999). Further, one of the trials did not publish
AF-specific data (Gadisseur 2003). Three studies reported deci-
sion conflict (Man-Son-Hing 1999; McAlister 2005; Thomson
2007), which measures (1) healthcare consumers’ uncertainty in
making a health-related decision; (2) the factors contributing to
the uncertainty; and (3) healthcare consumers’ perceived effective
decision making. However, one of the studies did not have a usual
care arm (Thomson 2007) and therefore was not included in the
pooled data analysis. One study reported self-efficacy (Polek 2012)
and one other study reported patient anxiety (Thomson 2007).
Another study reported mortality (Beyth 2000) but did not spec-
ify if death was due to a cardiovascular cause or any cause. One
study reported the number of thromboembolic or haemorrhagic
complications requiring medical treatment (Voller 2005).
None of the studies reported on:
• patient acceptability of anticoagulant therapy;
• changes in perception towards AF and INR control;
• changes in illness beliefs;
• illness perceptions;
• self-reported adherence to treatment;
• beliefs about the medication;
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• economic costs of the intervention.
Excluded studies
See the table ’Characteristics of excluded studies’.
Seventy studies were excluded for the following reasons.
1. Eighteen studies were excluded: four did not provide a break-
down of a mixed indication cohort per indication (McCahon
2011; Nilsson 2011; Vadher 1996; Vadher 1997), 14 studies did
not include AF patients (Baker 1991; Bump 1977; Claes 2005;
Claes 2006; Cordasco 2009; Cromheecke 2000; Cromheecke
2001; Fitzmaurice 2005; Holbrook 2007; Landefeld 1992;Mazor
2007; Pernod 2008; Waterman 2001).
2. Ten studies were eligible for inclusion but the data were inade-
quate as AF-specific findings were not presented, and attempts to
obtain the specific data from the authors were unsuccessful. For
nine of these studies: the authors could not be contacted (Stone
1989; Sawicki 1999; Watzke 2000), or did not respond to e-
mail or written requests for unpublished data (Barcellona 2006;
Chan 2006;Gardiner 2006;Menendez-Jandula 2005; Ryan 2009;
Siebenhofer 2007). For one study (Machtinger 2007) the author
was successfully contacted but the data were unavailable.
3. Twenty-six studies were not RCTs (Armstrong 2011; Bajorek
2005; Blaise 2009; Bloomfield 2011; Burns 2009; Castelino 2010;
Corbella 2009; Davis 2005; Duran-Parrondo 2011; Fraenkel
2011; Hasan 2011; Krause 2010; Leger 2004; Megden 1999;
Nedaz 2002; Polzien 2007; Reverdin 2011; Saokaew 2010; Satger
2009; Sawicki 2003; Taylor 1997; Tuiskula 2011; Winans 2010;
Witt 2005; Woodend 2005; Wurster 2006).
4. Sixteen studies did not fulfil our predefined inclusion cri-
teria. Four did not include an educational or behavioural in-
tervention (Field 2010; Fitzmaurice 1996; Fitzmaurice 2000;
Gouin-Thibault 2010; Matchar 2005; Trivalle 2010; Waterman
2001 b). Five studies provided education on self-monitoring alone
with no additional education on AF and the risks and benefits
of OAT (Christensen 2011; Dolor 2010; Grunau 2011; Matchar
2010; Sunderji 2005). None of the studies were excluded for in-
cluding participants < 18 years of age. Three studies did not re-
port any of the pre-specified outcomes (Batty 2001; Jackson 2004;
PRISM Study group 2003). One of the studies did not randomise
their usual care group (Khan 2004).
Three studies were eligible for inclusion but are ongoing trials and
their results are not yet available (Hua 2011; Smith 2010; Stafford
2011).
Risk of bias in included studies
See the table ’Characteristics of included studies’.
Risk of bias was assessed independently by two review authors
(DEC, DAL) in accordance with the Cochrane Handbook for Sys-
tematic Reviews of InterventionsVersion 5 (Higgins 2011). The risk
of bias for each of the included studies is summarised in Figure 2
and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six of the included trials provided information about adequate se-
quence generation. For the majority of trials this consisted of ran-
domisation to the intervention or usual care: according to a com-
puter-generated sequence using block randomisation (Christensen
2007; Man-Son-Hing 1999; McAlister 2005; Thomson 2007), a
random numbers table (Voller 2005), or a two-step partial-Zelen
design (Gadisseur 2003). The other two trials did not provide de-
tails of sequence generation (Beyth 2000; Polek 2012). One study
used cluster randomisation at the level of the family physician
(McAlister 2005). All eligible patients within any one physician’s
practice were allocated to the intervention (50 practices) or usual
care (52 practices). This process avoided contamination that may
have occurred if the same physician delivering the intervention
also delivered usual care. This trial also accounted for their ran-
domised clusters in their analysis, weighting the analysis accord-
ingly, thus their allocation was considered low risk of bias.
All of the studies reported the number of eligible participants.
However, for the mixed cohort trials it was difficult to retrospec-
tively assess which of the screened patients had AF. Of those trials
specifically recruiting AF patients, the percentage of eligible pa-
tients randomised ranged from7%(Khan2004a), 30%(Thomson
2007), to 49% (McAlister 2005). In the mixed indication cohort
trials this percentage ranged from 18% (Gadisseur 2003) to 95%
(Christensen 2007). Thus some of the trials were more represen-
tative than others. Those trials that included a small percentage of
eligible participants were at risk of selection bias whereby patient
characteristics may affect the study outcomes. For example, those
patients that participated may have been more motivated or will-
ing to participate.
Blinding
Blinding patients to the intervention they were receiving was not
possible with this type of intervention, nor was it possible to blind
the intervention facilitator to which arm the patients were in. This
inevitably raises the risk of bias for all studies. Experimenter bias
could have occurred in these trials, whereby the individuals deliv-
ering the intervention and usual care could behave differently to-
wards a group inadvertently affecting the study outcome.However,
blinding the data analyst or researcher to which intervention arm
the patient was assigned to was possible, in principle, and was un-
dertaken in four trials (Beyth 2000; Christensen 2007; Gadisseur
2003;McAlister 2005). Four trials did not state whether their data
analyst was blinded to which group the patients were randomised
to (Man-Son-Hing 1999; Polek 2012; Thomson 2007) or indeed
whether the individual delivering the intervention also carried out
the analysis, which inevitably increases the risk of bias.
Incomplete outcome data
The percentage of patients completing the final follow-up ranged
from 63% (Man-Son-Hing 1999) to 100% (Voller 2005). Where
attrition was greater than 20% this was considered a risk of bias.
If attrition is related to any feature of the study design, the instru-
mentation, or leads to bias between groups, this will increase the
risk of bias. Some of the self-monitoring and decision aid studies
reported participants as lost to follow-up due to an inability to
perform the tests or to understand the decision aid. Other rea-
sons included discontinuing warfarin, death, illness, and hospital-
isation. Where patients were unable to use the intervention this
could lead to a high risk of bias, with a more ’capable’ sample.
Selective reporting
Two of the studies published a protocol paper (McAlister 2005;
Voller 2005).McAlister reported on all but one of the pre-specified
outcomes (patient satisfaction). Voller and colleagues reported on
all of their pre-specified outcomes, although the trial was ended
early due to insufficient participant numbers to power the pri-
mary outcome (Voller 2005). A further six studies did not publish
protocol papers (Beyth 2000; Christensen 2007; Gadisseur 2003;
Man-Son-Hing 1999; Polek 2012; Thomson 2007), but reported
on all the outcomes specified within their method section.
Other potential sources of bias
Over the course of the study participants may change. With in-
creasing age the participants in these studies were likely to have suf-
fered from additional comorbidities and started taking new med-
ications. These trial designs cannot control for the impact of con-
comitant medications or the additional burden of newmedication
regimes across the study period, thus this may have increased the
risk of bias for all trials.
Effects of interventions
Various methods of measuring outcomes were employed and this
was the main obstacle when comparing study findings. This was
further complicated by the different time points at whichmeasure-
ments were taken, depending on the length of the trial. Further,
the included studies differed in type (behavioural and decision
aids) and in their comparator group.Where data were comparable,
that is using the same measurement tool and type of intervention,
AF-specific data were requested.
Education
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Percentage of time spent within the therapeutic range (TTR)
Two of the included trials compared education only and usual care
(Gadisseur 2003; Polek 2012). One of these trials reported TTR
(Gadisseur 2003).
Gadisseur et al (Gadisseur 2003) studied a cohort with a mixed in-
dication forOATandprovided additional unpublisheddata on the
AF cohort. They found that the TTR (SD) in the education only
group was higher than TTR in the usual care arm: 75.0% (18.5)
versus 67.1% (26.4), respectively; mean difference 7.9 (95% CI -
3.9 to 19.7).
Patient satisfaction
One education trial reported patient satisfaction (Gadisseur 2003).
However, the authors did not provide AF-specific data on patient
satisfaction for the education only group, thus it could not be
included within this narrative review.
Knowledge
One trial provided unpublished AF data on knowledge outcomes
(Polek 2012). They found slightly higher knowledge scores in
the intervention group than the usual care group at the 12-week
follow-up: 11.2 (1.6) versus 10.1 (1.7) respectively. However, the
number of AF patients in this mixed cohort was too small to draw
definitive conclusions.
Self-monitoring plus education
Percentage of time spent within the therapeutic range (TTR)
Four trials examined the impact of self-monitoring plus education
(Beyth 2000; Christensen 2007; Gadisseur 2003; Voller 2005).
Christensen (Christensen 2007) recruited patients with multiple
indications for OAT, with only 20 AF patients: 11 receiving self-
management plus education and nine in the usual care group. INR
control in the intervention group (mean (SD)) was slightly higher
in the intervention group than the usual care group: 77.3% (11.6)
versus 67.9% (23.5), respectively; mean difference 9.3 (95% CI -
7.5 to 26.2).
Gadisseur (Gadisseur 2003) was also a mixed cohort trial that
provided unpublished data on AF patients. TTR (mean (SD))
in the self-monitoring plus education group was slightly higher
than in the usual care group: 70.3% (18.7) versus 67.1% (26.4),
respectively; mean difference 3.2 (95% CI -13.7 to 20.2).
Beyth et al (Beyth 2000) did not provide AF-specific data on TTR
outcomes and thus could not be included in these analyses.
The pooled analysis of the two studies reporting TTR using the
Rosendaal method of calculation (Christensen 2007; Gadisseur
2003) demonstrated that self-monitoring plus education did not
significantly improve TTR when compared to usual care, mean
difference of 6.3 (95% CI -5.63 to 18.25) (Analysis 1.1; Figure
4).
Figure 4. Forest plot of comparison: 1 Time in therapeutic INR range, outcome: 1.1 Time in therapeutic
INR range.
Major bleeding, stroke and thromboembolic events
One study provided unpublished AF data on major bleeding,
stroke and thromboembolic events (Beyth 2000). Beyth and col-
leagues found the number of cases of major bleeding in the self-
monitoring plus education group (n = 1, 1.8% of total AF cohort)
was similar to the number of cases in the usual care group (n = 2,
3.7% of total AF cohort). There were also very few cases of stroke
and thromboembolic events in the self-monitoring plus education
(n = 1, 1.8% of total AF cohort) and usual care (n = 2, 3.7% of
total AF cohort) groups (Beyth 2000). Voller (Voller 2005) mea-
sured thromboembolic and bleeding events. Two severe haemor-
rhages occurred in one patient in the self-monitoring group, and
one thromboembolic event occurred in the usual care group.
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Time of INR values in therapeutic range
Voller (Voller 2005) measured time within range (in days) and
percentage of time in the INR target range, but did not calculate
TTR using the Rosendaal method. Values were in the target range
significantly more frequently (P < 0.01) in the patients under self-
management (67.8%) than in the family doctor group (58.5%).
There was a trend, but no significant difference, with regard to
the number of days within the target range (178 ± 126 days as
compared to 155.9 ± 118.4 days).
Education versus self-monitoring (plus education)
Percentage of time spent within the therapeutic range (TTR)
One trial compared self-monitoringplus educationwith education
only (Gadisseur 2003).
Gadisseur (Gadisseur 2003) provided unpublished data on AF
patients that suggested the TTR was slightly higher (mean (SD))
in the self-monitoring group than in the education only group:
71.1% (14.5) versus 70.4% (24.5); mean difference of 0.7 (95%
CI -7.9 to 9.3).
Decision aids
Percentage of INRs in range
One trial reported the percentage of INRs in range (McAlister
2005). Percentage of INRs within the therapeutic range differed
from TTR as the outcome was not calculated using the Rosendaal
method (Rosendaal 1993).McAlister (McAlister 2005) found that
INR control deteriorated in the usual care arm over time (INRs
were between 2 and 3 on 66% of the days at 3 months versus
70% of the days at baseline), while INR control improved in
the intervention arm (INRs were between 2.0 and 3.0 on 72%
of the days at 3 months versus 65% at baseline) over time. The
between group difference was statistically significant (P = 0.02).
By 12 months, INR control in both arms had regressed back to
baseline levels.
Increased knowledge
Two trials reported on patient knowledge (Man-Son-Hing 1999;
Thomson 2007). Thomson (Thomson 2007) used an extension
of the decision conflict scale (O’Connor 1995) and found that
although knowledge scores after the intervention had improved
slightly, by three-month follow-up they had returned to pre-in-
tervention levels. There was no significant difference between the
decision aid and guidelines groups at any point.
The second trial used a non-validated scale and demonstrated that
patients in the decision aid group had significantly greater knowl-
edge of treatment-related information: aspirin-related difference
15.9 (95%CI 4.6 to 27.2, P < 0.001); warfarin-related 14.9 (95%
CI 4.6 to 25.2, P < 0.001) than those in the usual care group
(Man-Son-Hing 1999).
Patient satisfaction
One trial using a decision aid intervention reported patient sat-
isfaction as an outcome (Man-Son-Hing 1999). They found that
the use of the decision aid did not significantly affect patients’
satisfaction with their physician consultations.
Decision conflict
Three studies (Man-Son-Hing 1999; McAlister 2005; Thomson
2007) reported decision conflict, and all used the decision conflict
scale (O’Connor 1995).
Man-Son-Hing (Man-Son-Hing 1999) found that the usual care
arm scored slightly higher (mean (SD)) on decision conflict than
the decision aid arm: 1.74 (0.5) versus 1.6 (0.4); mean difference
-0.09 (95% CI -0.2 to 0.02).
McAlister (McAlister 2005) found that the usual care arm scored
slightly higher (mean (SD)) on decision conflict that the decision
aid arm: 1.7 (0.5) versus 1.6 (0.5); mean difference -0.10 (95%
CI -0.19 to -0.01).
Although three studies reported decision conflict as an outcome
(Man-Son-Hing 1999, McAlister 2005; Thomson 2007), only
two compared differences in the usual care and decision aid inter-
vention groups (Man-Son-Hing 1999;McAlister 2005). The third
compared the decision aid with a guideline comparison group
(Thomson 2007) and therefore was not included in themeta-anal-
ysis. Data from the two trials (Man-Son-Hing 1999; McAlister
2005) were pooled and the analysis favoured usual care in terms of
reducing decision conflict: mean difference -0.10 (95% CI -0.17
to -0.02) (Figure 5; Analysis 2.1).
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Figure 5. Forest plot of comparison: 2 Decision conflict, outcome: 2.1 Decision conflict.
Anxiety
Only one trial reported anxiety as an outcome (Thomson 2007).
Anxiety fell significantly in both groups pre- to post-clinic, mean
change -4.57 (95% CI -6.30 to -2.84), but there was no evidence
of a significant difference in anxiety between the two groups (F
(1, 95) = 0.001; P = 0.98).
D I S C U S S I O N
Summary of main results
This review found eight RCTs (Beyth 2000; Christensen 2007;
Gadisseur 2003; Man-Son-Hing 1999; McAlister 2005; Polek
2012; Thomson 2007; Voller 2005) of behavioural and educa-
tional interventions for anticoagulant therapy in patients with AF.
Two trials compared education with usual care (Gadisseur 2003;
Polek 2012), four compared self-monitoring plus education with
usual care (Beyth 2000; Christensen 2007; Gadisseur 2003; Voller
2005), and one trial also compared a self-management group (con-
sisting of self-testing and self-dosing) (Gadisseur 2003). Three tri-
als focused on the use of a decision support aid versus usual care
(Man-Son-Hing 1999; McAlister 2005) or a comparison group
(Thomson 2007). The analyses included a small number of trials
with small sample sizes, thus more evidence is needed to draw
definitive conclusions.
Self-monitoring plus education versus usual care
Two self-monitoring plus education trials reported TTR (
Christensen 2007; Gadisseur 2003). Pooled data for the AF pa-
tients demonstrated that self-monitoring plus education did not
significantly improve TTR when compared to usual care (OR 6.3,
95% CI -5.63 to 18.25) (Analysis 1.1). One previous Cochrane
review compared self-management (monitoring and dosing) and
self-monitoring (monitoring only) interventions for mixed indi-
cation patients taking OAC. In their pooled data analysis, self-
management interventions showed significant reductions in both
thromboembolic events (RR 0.50, 95% CI 0.36 to 0.69) and all-
cause mortality (RR 0.64, 95% CI 0.46 to 0.89), but self-mon-
itoring did not (Garcia-Alamino 2010). The findings from the
current review support those by Garcia-Alamino and colleagues
that in an AF cohort self-monitoring is no more successful in in-
creasing INR control than usual care.
Decision aids
Decision aid trials favoured usual care over the intervention in
minimising decision conflict (mean difference -0.10, 95% Cl -
0.17 to -0.02). The use of a decision aid did not have a signif-
icant impact on AF patients’ anxiety levels (Thomson 2007) or
patient satisfaction (Man-Son-Hing 1999). This suggests that pa-
tients that took part in the decision aid trial were uncertain about
the decision as to which treatment choice theywere going tomake.
Overall completeness and applicability of
evidence
Four of the included trials had mixed indication cohorts (Beyth
2000; Christensen 2007; Gadisseur 2003; Polek 2012), and 10
further trialswere excluded as they did not provideAF-specific data
(Barcellona 2006; Chan 2006; Gardiner 2006; Machtinger 2007;
Menendez-Jandula 2005; Ryan 2009; Sawicki 2003; Siebenhofer
2007; Stone 1989; Watzke 2000). Recruiting patients with mixed
indications for warfarin can be problematic. Patients often have
different INR ranges (for example with valve replacements) and
each patient group is unique in their lifestyle and treatment recom-
mendations. AF patients are often older (Kannel 1998), prescribed
treatment on a long-term basis (NICE 2006), and susceptible to
inaccurate beliefs surrounding their illness (Steed 2010) due to
their symptoms being irregular and often unrecognised (Fuster
2006). Thus it is essential that interventions are disease specific,
yet only one of the included trials specificallymentioned educating
the patients about AF (McAlister 2005). Without discussing the
illness itself patients may not understand the need for treatment
and the associated risks of their condition. Those interventions
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that are disease specific may prove more successful in targeting the
particular concerns of the target population.
A further consideration is that the participants in these trial cohorts
may exhibit a number of co-morbidities which have not been ac-
counted for, thus theymay have received similar behaviour change
interventions in the past for conditions such as diabetes poten-
tially increasing their knowledge and awareness of risk. Therefore,
the results of these trials may not be representative of the effect a
behavioural or educational intervention may have on a sample of
warfarin-naive AF only patients, and we cannot draw conclusions
on the use of interventions for newly referred patients who are at
greatest risk of complications.
Patients that self-monitor are also educated to ensure they are
able to perform the tests accurately and safely. It is therefore dif-
ficult to determine whether the education or the self-monitoring
is improving health outcomes. Further, patients selected for self-
monitoring tend to be younger, healthier, and better educated.
Thus they may not be representative of a general AF population
(Garcia-Alamino 2010). Similarly, decision aids provide patients
with education regarding treatment choices thus it is difficult to
determine whether increases in knowledge alone may have the
same effect. The delivery of the intervention could also influence
the outcomes; a group-based intervention provides opportunity
for social comparison, which influences patient attitudes towards
their treatment and their perception of social norms.
All of the trials recruited patients that had been previously tak-
ing OAT. Whilst some trials included warfarin-naive patients
(Thomson 2007) or inpatients starting OAT (Beyth 2000; Polek
2012), none of the trial cohorts were exclusively warfarin-naive.
Experience of taking warfarin could increase the risk of poor in-
ternal validity as patients may had been receiving OAT treatment
long term, for up to 5.5 years (Christensen 2007) prior to receiving
the intervention, andmay be influenced by their treatment history
(for example side effects). Previous experience of the treatment
may also influence their levels of adherence to recommendations,
and a patient’s decision to start taking the treatment in the first
place (Holbrook 2005; Lip 2011). Patients may develop specific
beliefs about their medications that influence the decision making
process, such as the inconvenience of regular blood tests, need for
reductions in or abstinence from alcohol, and dietary restrictions
(Dantas 2004; Lane 2006; Lip 2007; Lip 2011). Patients may also
feel a level of protection from harm by taking a treatment (Lip
2011), thus increasing their likelihood of adopting one treatment
over another. One of the trials in this review recruited patients that
had previously taken part in the Stroke Prevention in Atrial Fib-
rillation (SPAF) trial (Man-Son-Hing 1999). All of these patients
had previously taken either an antiplatelet drug (60% of decision
aid group versus 60% of the usual care group) or OAT (37% of
the decision aid group versus 38% of the usual care group). The
participants within this trial are unlikely to be representative of
patients that are making treatment decisions for the first time.
Firstly, they are ex-trial patients and may be more likely to have
hadprior treatment-related education and, secondly, they have had
first-hand experience of one or both treatments. One study found
that more patients chose warfarin in a decision aid trial when the
drug name was blinded than when it was unblinded (Holbrook
2007), suggesting that patients are influenced by prior knowledge,
beliefs surrounding medications, and perhaps any adverse events
they may have suffered from. Research suggests that patients are
more likely to choose their current treatment over and above an-
other; it has been suggested that this act prevents cognitive dis-
sonance (that is the stress of choosing a preferred treatment over
actual treatment choice) (Fuller 2004; Holbrook 2007; Howitt
1999; Protheroe 2000).
Quality of the evidence
Two types of bias were most prevalent within the studies. Firstly,
blinding of patients to the intervention received was not possible,
nor was it possible to blind the intervention facilitator, inevitably
raising the risk of bias. It is unclear whether the researchers may
have biased patient outcomes by treating the patients in the inter-
vention arm differently from those in the control group. Blinding
the data analyst or researcher to which intervention arm the pa-
tient was assigned to was undertaken in four trials (Beyth 2000;
Christensen 2007; Gadisseur 2003; McAlister 2005). Trials must
be explicit when reporting their methods and procedures to en-
sure accurate assessment of blinding bias and enable comparison
of trials.
Inclusion bias was also evident inmany studies, where the trial par-
ticipants may not have been representative of the eligible partici-
pants. The percentage of eligible patients randomised was as low
as 18% (Gadisseur 2003) in one of the mixed cohort trials. Per-
haps the reluctance of individuals to participate may relate to the
extensive training required, particularly for self-monitoring trials.
Furthermore, many patients may refuse consent due to physical
limitations, the time commitment associated with multiple train-
ing sessions, or psychological barriers to performing self-monitor-
ing. AF patients in particular are mostly elderly (Kannel 1998),
and often highly symptomatic (Lip 2011), thus trial participation
may be a burden. This could explain the small AF sample sizes in
the included mixed OAT indication trials, as patients with other
indications may be younger and with fewer co-morbidities.
The quality of care in the control groups may vary, affecting the
benefit and control of standard anticoagulation monitoring. The
educational element of the intervention may be one of the key
factors in improving TTR. However, trials vary in the intensity,
duration, and number of education sessions, thus we cannot draw
conclusions about the influence of each of the educational com-
ponents of these interventions.
Five studies did not record patients’ level of education (Christensen
2007; Gadisseur 2003; Polek 2012; Thomson 2007; Voller 2005),
a factor which may impact on knowledge uptake and treatment
control. Research suggests that patients with greater knowledge of
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their treatment spend more time in the therapeutic range (Tang
2003). Thus the results of the trials that do not indicate education
level may be influenced by individual differences in educational
achievement between trial groups.
Whilst the educational components of the interventions did focus
on important areas of risk (that is side effects, medication recom-
mendations), they did not include education specific to the pa-
tient’s indication for treatment. Studies suggest that AF patients
have limited knowledge of their condition (Coehlo-Dantas 2004;
Lane 2006; Nadar 2003; Tang 2003), which may influence the
perceptions they formabout their illness and their treatment (Steed
2010). Thus it is essential that patients form accurate concepts of
their illness and make appropriate lifestyle changes.
Few studies provided AF-specific data on psychological outcomes
such as anxiety, depression, and quality of life. Those that did
found no significant differences between groups. Only one deci-
sion aid trial reported anxiety as an outcome (Thomson 2007).
Thomson found that anxiety fell significantly in both groups from
pre- to post-clinic, mean change -4.57 (95% CI -6.30 to -2.84),
but there was no evidence of a significant difference in anxiety
between the two groups (F (1, 95) = 0.001; P = 0.98). None of the
self-monitoring trials measured anxiety, a factor which may have
an influence on patients’ self-efficacy to perform regular blood
tests. Numerous studies suggest that AF patients suffer from high
levels of anxiety (Thrall 2004), yet none of the interventions were
designed with this in mind. As evidence suggests that AF patients
often have inaccurate illness representations (Steed 2010), trials
of interventions that include psychological components and out-
come measures are needed.
Potential biases in the review process
Our search strategy included a comprehensive search of several
electronic databases, meticulous handsearching of reference lists
of included and excluded papers, recent conference proceedings,
and personal communications with experts in this area. In addi-
tion, we wrote to all the authors of included studies requesting
AF-specific data and further demographic and clinical details on
the included cohorts. Further, the titles and abstracts of all studies
identified by the search strategy were reviewed independently by
two review authors and disagreements were resolved by consen-
sus. Data extraction of the included studies was also undertaken
independently by two review authors. Therefore, we believe that
the potential for bias in the review process was minimal and that
it unlikely that we have missed important studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Patients participating in both educational interventions and self-
monitoring interventions (with education) appear to spend more
time within the therapeutic INR range, but pooled analyses of the
AF data did not favour self-monitoring plus education over usual
care. Evidence is limited as only a few trials with small samples
of AF patients were included. More trials are needed to exam-
ine the impact of intensive educational interventions on antico-
agulation control in AF patients and the impact on TTR. Self-
monitoring may not be a feasible option for many patients, par-
ticularly as it requires additional training (Fitzmaurice 2000), is
costly (Fitzmaurice 2000), and new anticoagulants are now avail-
able which do not require monitoring (Lip 2011; Shantsila 2010).
Further, one of the newer oral anticoagulants (NOAC) trials, where
dabigatran was compared with warfarin, examined the TTR of
those patients taking warfarin and compared the event rates by
quartile of centre TTR (cTTR) (Wallentin 2010) and demon-
strated that despite very good cTTR (> 72.6%) both doses of dabi-
gatran were associated with fewer adverse events than warfarin.
However, there will still be some patients for whom the NOACs
are not suitable (for example those with severe renal impairment),
where warfarin would be the only alternative OAC treatment.
However, no study todate has compared self-monitoringwithwar-
farin to treatment with dabigatran on adverse events (stroke and
major bleeding) and therefore it is unclear whether there would
be a benefit of self-monitoring with warfarin (in the appropriate
patient) over treatment with dabigatran.
Implications for research
This review highlights the need for AF-specific trials in larger co-
horts and among warfarin-naive AF patients. The number of AF
patients within the trials was limited with most patients being
warfarin-experienced. Furthermore, the trials that were included
primarily focused on self-monitoring plus education or decision
aids. None of the trials specifically looked at other types of inter-
ventions such as intensive education or behaviour change inter-
ventions that are driven to improve psychological outcomes (that
is motivational interviewing and cognitive behavioural therapy).
Trials also need to consider the use of disease-specific measuring
tools, whichmay provide amore accurate assessment of the impact
of the intervention. In addition, such trials should account for the
potential confounding effects of level of education and the quality
of the care in the control group.
Ongoing trials
A trial currently being undertaken by the review authors has re-
cruited warfarin-naive AF patients and has specifically examined
the effects of an intensive educational intervention to gain an un-
derstanding of the impact of an intervention during this ’high
risk’ phase of treatment (Smith 2010). Other ongoing trials have
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focused on education (Hua 2011) and an enhanced patient dis-
charge system (Stafford 2011). These trials may provide additional
evidence and insight for later review updates. We will update this
review once the results from these studies are published. In ad-
dition, for the results to be generalisable to the AF population
there is a need for population-based studies that collect data on
adverse event rates, time in range, and cost effectiveness, factors
that impinge on successful educational and behavioural interven-
tions. Future studies should set out to understand themechanisms
by which interventions are successful by exploring the psycholog-
ical and practical implications for AF patients commencing OAC
treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beyth 2000
Methods Randomised, controlled, parallel-groups design
Participants N randomised: 132 versus 162 usual care
Diagnosis of ppts: AF n=54 (16.6%) for the intervention group and usual care groups.
Other indications include venous thromboembolism, cerebrovascular disease, heart valve
prosthesis, peripheral vascular disease, myocardial infarction
Demographics for total cohort:
Age:74.9±6.9 versus 74.5±6.6
% female: 55 versus 59% usual care
% white: 69% versus 65% usual care
Mean number of school years 12.1±4.4 [intervention], 12.1±4.1 [usual care]
Demographics for AF patients:
Age: 74.6±6.8 intervention versus 75.5± 6.2 usual care
% female: 40% versus 66% usual care
% white: 77% versus 77% usual care
Mean number of school years 14.5±4.9 [intervention], 12.0±3.9 [usual care]
Inclusion/exclusion criteria: Patients hospitalised and receiving 10000 units or more
of intravenous heparin, were 65 years or over, for whom warfarin treatment was planned
for 10 days or more. Patients were excluded if they had been treated with warfarin at
any time in the previous 6 months, were admitted from a nursing home, were enrolled
in another clinical trial, were too ill to give consent or did not speak English
Interventions Type: Guideline-based consultation, Education and self-monitoring
Content: A consultation that assessed the patients indication for therapy and potential
risks for warfarin related bleeding (a method used by the researchers previously). This
included specific recommendations about modifiable risk factors, such as use of non-
steroidal anti-inflammatory drugs.The other component included patient education,
coaching and self monitoring. Patient education consisted of one to one teaching by
a lay educator using a specifically formatted workbook for older adults to teach them
about warfarin, indications for its use, drug and food interactions, and the signs and
symptomsof bleeding.Coaching aimed to increase patients participation in their care and
improve information seeking-skills. Self-monitoring of prothrombin time (grounded in
social learning theory). Patients were taught to self-monitor prothrombin time. Patients
instructed to use monitor 3 times in first week and once weekly after that
Duration: 30 minutes-1 hour (consultation)
Facilitator: lay educator
Setting: hospital
Outcomes Incidence of major bleeding
Excessive anticoagulation
Rates of VTE
Country Cleveland, Ohio, USA
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Beyth 2000 (Continued)
Comparison Usual care group
Length follow-up 6 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were stratified according to their
baseline risk for major bleeding by using
the outpatient bleeding risk index. The
index includes 4 independent risk factors
for major bleeding: age 65 or older, his-
tory of gastrointestinal bleeding, history of
stroke, and one or more of four specific
comorbid conditions (myocardial infarc-
tion, hematocrit<30%, creatinine concen-
tration> 133µmol/L (1.5mg/dL), or dia-
betes mellitus). Patients with one or two
risk factors were classified as intermediate
risk, and those with 3 or more risk factors
were classified as high risk; estimated fre-
quencies of major bleeding in 6 months
were 6% and 35% respectively
Allocation concealment (selection bias) Low risk 426 eligible patients were identified, 294
(69.0%) received either usual care or the
intervention. This indicates low risk of se-
lection bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk The educational intervention was delivered
by a lay educator that was not involved in
the treatment of the patients
Incomplete outcome data (attrition bias)
All outcomes
High risk 81% (n=132) of the 163 patients assigned
to the intervention group participated in
the intervention. 12 patients felt more
comfortable with venipuncture, 3 stopped
warfarin during hospitalisation, and 1 was
discharged to a nursing home that pre-
cluded the use of a portable monitor. At 6
months 21 patients (13%) in the interven-
tion group and 26 (16%) of the usual care
group had died
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Beyth 2000 (Continued)
Selective reporting (reporting bias) Low risk The method section describes the primary
outcome as first major bleeding event dur-
ing the 6 month intervention period. Sec-
ondary outcomes were death and recurrent
VTE at 6 months; major bleeding after 6
months and INR control during the first 6
months of therapy. The authors report data
on all of these outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants cannot be blinded to which
arm of the trial they receive. Neither can
the personnel delivering the intervention
be blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trained abstractors who were not involved
with the intervention component of the
study collected data from the medical chart
at the start of OAC, and by blinded inter-
view at enrolment at 1, 3, 6 months af-
ter enrolment and every 6 months there-
after. Whenever an event was reported, the
clinical characteristics of the bleeding or
thromboembolic episode were determined
by reviewof the relevantmedical record and
abstracted without identifying the patient
onto a standard form
Christensen 2007
Methods Open-label randomised controlled trial, cross-over (6 months)
Participants N randomised: 47 versus 45 (usual care/conventional management)
AF: n=11 versus n=9 (usual care), other indications include mechanical heart valve,
coagulopathies, VTE, synthetic vascular graft
Demographics for total cohort:
Age: 51.5±14.4 versus 46.3±13.4 (usual care)
% female: 23% versus 44% (usual care)
% white: not stated
% education above primary level: not stated
Demographics for AF cohort:
Age (SD): 59 (18) versus 51 (12)
% female: 0% intervention versus 7% usual care
% white: 100% in both groups
% high school or greater: 4% versus 3% usual care
Inclusion/exclusion criteria:
Patients were eligible if they were referred for patient self-management by a general
practitioner or hospital department, treated with oral anticoagulants >8months, 18 years
or over, willing to be randomised. Patients were excluded if they had previously used
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self-management or lived abroad
Interventions Type: Teaching lesson (not explained in detail) and patient self-management (PSM)
Content: The group usedCoagucheck, which displays the INRvalue after the application
of a drop of blood. Self-management training included patient practicing analysis of
blood specimens. The patient gradually assumed management of OAC. After 27 weeks
patients took an exam, if passed patient went on to self-manage. After 6 months the
conventional management group started the same training
Duration: not stated
Facilitator: not stated
Setting: hospital
Outcomes Major complications (bleeding and thromboembolism requiring intervention)
Death and/or discontinuation of the study
Primary endpoint: variance of INR in trial and control samples
TTR
Country Aarhus, Denmark
Comparison Conventional management
Length follow-up 0bservation period
1) 8-12 months before randomisation
2) primary observation period (6 months of either patient self-management or conven-
tional management)
3) patient self-management training (27 weeks)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned to pa-
tient self-management using a comput-
erised, prospective, randomisation sched-
ule. Randomisation in blocks with various
sizes in numbers of 2,4, and 6 was used
Allocation concealment (selection bias) Low risk 105 patients were eligible to take part in the
study and 100 patients were randomised
(95%), therefore there is a low risk of selec-
tion bias
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk It was unclear whether the personnel deliv-
ering the intervention was also involved in
treating the usual care arm
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Incomplete outcome data (attrition bias)
All outcomes
Low risk In the self-management arm three patients
dropped out, two during the training pe-
riod, and one died. In the usual care arm of
the study one patient was withdrawn by the
physician and four dropped out during the
self-management training. Thus 92% of
original cohort participants were included
in the analysis
Selective reporting (reporting bias) Low risk The endpoints were the variance (mean
square of standard deviation) of the INR
value, the median INR value (using a
blinded control sample analysed monthly
by a reference laboratory) and the coumarin
dose. All outcomes were reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Due to the nature of the intervention,
the participants receiving the intervention
and the personnel delivering it cannot be
blinded to which arm of the intervention
they are in
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk External control blood samples were
blinded. The results of the INR analysis
was blinded for all except one secretary who
would ensure the safety of the patient by
contacting the managing physician if the
INR value was below 1.5 or above 4.5
Gadisseur 2003
Methods Multicentre randomised study, 4 arms
Participants N randomised: A) weekly self-measurement n=52; B) weekly self measurement and self-
dosing n=47; C) educated routine care n=60; D) existing routine care (not trained) n=
161. This study used a Zelen design
Diagnosis of ppts: number of AF patients in group A=6 (11.6%), group B=9 (19.2%),
group C=10 (16.6%), and group D=43 (26.7%). Other indications included DVT, PE,
artificial heart valves, vascular prosthesis
Demographics for total cohort:
Age: mean age A=54.8 (25-74), B=53.9 (24-75), C=56 (21-73), D=62 (32-75)
% female: A=23%, B=32%, C=40%, D=46%
% white: not stated
% education above primary level: not stated
Demographics for the AF patients: not provided
Inclusion/exclusion criteria:
At least >3 months of OAT experience, need for long-term OAT, aged 18-75. Patients
were excluded if they had antiphospholipid syndrome, a life threatening illness, life ex-
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pectancy≤1 year, diminished understanding, and physical limitations making successful
participation impossible
Interventions Type: self-management and self-dosing including education
Content: They received information about the study, the blood coagulation system,
OAT, and the effects of some substances (eg. alcohol, certain medications and foods rich
in vitamin K) on OAT; then they were also taught how to use Coagucheck device, and
instructed on oral self-dosing of phencoumon and acenocoumarol. This also contained
practical information about working with the Coagucheck, information about the co-
agulation system, theoretical and practical self-dosing training. They were also given
written information on all the topics discussed
Group A: weekly INR self-measurement, but dosing was performed by anticoagulation
clinic physicians. Patients reported their INR values by telephone to the anticoagulation
clinics. Dosing schedules communicated via telephone
Group B: this group self-managed their OAT, patients informed the anticoagulation
clinic of their INR measurements, proposed dosing schedules and reported any relevant
information or complications. Patients were contacted via telephone to confirm whether
they could adhere to their proposed dosing schedule or if they needed to adjust it
Group C: patients were trained for inclusion in groups A or B but stayed with the
routine care system. Measurements of INR and dosing were done by anticoagulation
clinic physicians, and the interval between INRmeasurements depended on the stability
of the INR values
Group D: patients in this group were unaware of their participation in the study, repre-
senting the existing care system
Duration: 3 training sessions, groups of 4-5, 90-120 minutes
Facilitator: delivered by physician, paramedical person
Setting: hospital
Outcomes Quality of life (questionnaire developed by Sawicki et al), 32 items, validated. The
questionnaire was meant to measure patient concerns, the impact of self-monitoring of
INR, and the possibility of increased education. Translated from German to Dutch and
marginally altered for relevance in the Netherlands
Country Netherlands
Comparison A) weekly self-measurement
B) weekly self-measurement and self-dosing
C) educated routine care
D) existing routine care (not trained)
Length follow-up Mean follow-up time 24.5 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk The patients were selected by groups of 40 and
randomised to 4 treatment groups (A, B, C and
D) following a 2-step partial zelen design
Allocation concealment (selection bias) High risk Of the 881 eligible participants, 159 (18%)
were randomised, therefore this study is at high
risk of inclusion bias. 916 patients were ran-
domly selected by a computer, 35 (3.9%) were
excluded because of intellectual or physical
limitations or because of a life expectancy of <
1 year
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The authors do not state whether those physi-
cians delivering the intervention also treated
the usual care arm
Incomplete outcome data (attrition bias)
All outcomes
High risk 116 (64%) of the original 180 patients ran-
domised to the study completed the quality of
life questionnaires at baseline and follow-up.
21 patients were withdrawn or ineligible and
the remainder were lost to follow-up
Selective reporting (reporting bias) Unclear risk Pre-specified endpoints were (1) quality of
OAT represented by the number of INR read-
ings within target range (TTR); (2) patients
ability to independently performanticoagulant
self-dosing, by number of dosage corrections
made. All specified outcomes were reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients who were not randomised to group
D were sent a letter with written information
about the study (thus not blinded). Knowledge
of the composition of the different groups was
restricted to a few nurses who were also respon-
sible for anonymously transferring the dosing
schedules for group A and group B patients to
standard forms and faxing them to the other
participating anticoagulation clinics. The pa-
tients and staff could not be blinded to which
arm of the trial participants were assigned to
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The physicians evaluating and correcting the
proposed dosing schedules for group A and B
were unaware of the originators of these sched-
ules. The INR values of the patients in routine
care groups C andDwere entered into the rou-
tine computerised system in such a way that
the dosing physicians could not distinguish be-
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tween these and the general patient population
Man-Son-Hing 1999
Methods Randomized controlled trial
20 possible SPAF trial centres invited, 14 participated
Participants N randomised: intervention n= 139 (10 lost to follow-up); control n=148 (14 lost to
follow-up)
Diagnosis of ppts: all atrial fibrillation
Demographics of cohort:
Age: intervention mean=65, control mean=65
% female: intervention 24%, control 24%
% white: not stated
% education above primary level: intervention 90% high school education or greater,
control 91% high school education or greater
Inclusion/exclusion criteria: all participants were in the SPAF III aspirin cohort study
and were eligible unless they had high risk criteria or had a major haemorrhage during
the study
Interventions Type: decision aid
Content: 29 page booklet, a personal worksheet (complete pre-intervention), 20-minute
audiotape that guided the patient through the booklet and worksheet. The intervention
included a description of the consequences of minor/major stroke and major haemor-
rhage, the blood monitoring required for warfarin and the 2-year probability of stroke
and major haemorrhage for patients taking aspirin/warfarin using pictograms
Duration: not stated
Facilitator: physician/audio tape
Setting: hospital
Outcomes 1-4 days after meeting with their physicians patients completed questionnaires
Patient choices (strength of their decisional input, 5-point Likert scale, unvalidated)
Knowledge (23 questions about AF, stroke and treatment, unvalidated)
Expectations (4 questions regarding patient expectations of stroke/haemorrhage, unval-
idated)
Decisional conflict (decisional conflict scale, ref: O’Connor 1995)
Satisfaction (6 questions, 5-point Likert scale, unvalidated)
Six-month adherence to their treatment decisions (self-report brief questionnaire, ad-
ministered via telephone, unvalidated)
Country US
Comparison Control group, usual care, i.e. no change was made to the usual manner in which each
centre communicated the results of the SPAF III study or the way in which the decision
regarding type of antithrombotic was made
Length follow-up 6-month follow-up
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated scheme, adminis-
tered from a central location to block se-
quence from previewing. Stratified by cen-
tre and the presence of a history of hyper-
tension
Allocation concealment (selection bias) High risk 657 patients were eligible for the trial, 287
participated (43%), giving a substantial risk
of inclusion bias. 24 participants were lost
to follow-up
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The authors do not state whether those
physicians delivering the intervention also
treated the usual care arm
Incomplete outcome data (attrition bias)
All outcomes
Low risk 87 (63%) worksheets from 139 patients
participating were completed. However, all
of the 139 patients randomised to the deci-
sion aid were included in the study analysis
of decision conflict
Selective reporting (reporting bias) Low risk Outcome measures were patients’ ability
to make choices regarding antithrombotic
therapy, 6-month adherence to decision,
knowledge, decision conflict and satisfac-
tion. There was no protocol paper for this
study. However, one of the pre-specified
outcome variables in the method section
was not reported (patient satisfaction)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors do not state whether the
researcher or personnel were blinded to
which arm the participants were ran-
domised to. However, we can assume
that participants and physicians were not
blinded to treatment allocation due to the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors do not state whether the per-
sonnel scoring and analysing the question-
naires were blinded to the treatment allo-
cation
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McAlister 2005
Methods Prospective, multicentre, two-arm, cluster randomised trial.
Participants N randomised: intervention n=219, control n=215
50 GP practices were randomised to the decision aid group and 52 were randomised to
usual care
Diagnosis of participants: All NVAF (also broken down type of AF, see paper)
Demographics of cohort:
Age: intervention 73±9; controls 71±10
% female: intervention 43%, controls 34%
% white: not stated
% education above primary level: completed high school: intervention n=84 (38%),
usual care n=72 (33%)
Inclusion/exclusion criteria: community-dwelling patients, over the age of 18, will
be included in this study if they have a diagnosis of NVAF (intermittent or chronic)
confirmed by ECGor prescription for digoxin. Theywere excluded if they had 1) valvular
AF; 2) taking warfarin for another condition; 3) are scheduled for cardioversion; 3)
have a contraindications for warfarin or aspirin; 4) cognitive impairment; 5) their life
expectancy is less than 12 months; 6) cannot understand/converse in English
Interventions Type: general education session plus patient decision aid and physicians manual
Content: 30-page decision aid booklet, personal worksheet, 50-minute audiotape to
guide participants through the booklet and worksheet, and a 7-page physicians manual
summarising the evidence discussed in the patient booklet with a focus on the 2001
ACCP risk stratification schema and recommendations for antithrombotic therapy. 4
versions of the decision aid were available depending on patient’s baseline stroke risk.
All four versions provide the same background information about AF; the potential
consequences of stroke and major haemorrhage, relative efficacy/bleeding risks with
warfarin and aspirin therapy. Key points are further elaborated upon in the audio-tape.
The 1 page worksheet is to be completed by the patient after reviewing the booklet to
clarify their personal values regarding desired outcomes, the therapy they are inclined to
take, their preferred role in the decision process, and any questions they have for their
physician
Duration: not stated
Facilitator: physician
Setting: GP practices
Outcomes Use of appropriate antithrombotic therapy at 3 months, as defined by the 2001 ACCP
recommendations. Secondary outcomes include (1) appropriate antithrombotic therapy
at 6months and12months, (2) patient’s readiness tomake a choice at baseline (previously
validated questionnaire, with reference), (3) patient knowledge after the intervention
(multiple-choice responses used in previous trial, with reference), (4) decisional conflict
- decision conflict scale (O’Connor), (5) acceptability of decision aid (9 questions with
variable responses on a 5-point Likert scale), (6) satisfaction (5-point Likert scale), (7)
adherence with therapy (validated Morisky scale with modified 5-point Likert scale
response)
Country Canada
Comparison Usual care
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Length follow-up 1-year follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation to intervention or usual
care is being carried out according to a com-
puter-generated sequence using clustered
block randomisation (block size of four)
with allocation concealment
Allocation concealment (selection bias) High risk 904 patients were eligible for the study. 446
patients were randomised (49%). Due to
the number of patients declining screening,
there is an increased risk of inclusion bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Physicians that delivered the intervention
did not treat the usual care arm
Incomplete outcome data (attrition bias)
All outcomes
Low risk 446 eligible participants were randomised.
434 (97%) were included in the 3-month
follow-up evaluation
Selective reporting (reporting bias) Low risk The primary endpoint was use of appro-
priate antithrombotic therapy, other end-
points include TTR, patients readiness to
make choices, knowledge, decision con-
flict, acceptability of decision aid, satisfac-
tion, and adherence. Adherence and satis-
faction scales data are not explained in de-
tail. However, authors report the majority
of data from the protocol paper including
key primary and secondary outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors do not state whether the
researcher or personnel were blinded to
which arm the participants were ran-
domised to. However, we can assume
that participants and physicians were not
blinded to treatment allocation due to the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessment was carried out
by an independent statistician who was
blinded to group allocation
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Polek 2012
Methods Nested randomised controlled trial
Participants N randomised: intervention=25, usual care = 28
Mixed indication cohort
Demographics of the cohort:mean (SD) age = 63.71 (16.04)
% female: not stated
% white: not stated
% educated above primary school level: not stated
Demographics of the AF patients: N=14
Treatment group n= 5; usual care n= 9
Age, mean (SD): intervention = 73.6 (11.1), usual care = 76 (13.4)
% female: intervention = 4/5 (80%), usual care = 3/9 (33%)
% white: intervention = 3/5 (60%), usual care = 5/9 (55%)
% educated above primary school level: not available
Inclusion criteria: patients discharged to home on OAT, alert and orientated, able to
speak and understand English, and accessible via telephone
Exclusion criteria: patients discharged to a nursing home or rehabilitation facility, his-
tory of psychotic disorder or cognitive impairment
Interventions Type: Enhanced educational intervention
Content: face-to-face warfarin education, printed materials, instruction, medical alert
bracelet. The intervention was based on Banduras social cognitive model and aimed to
improve self-efficacy. Four post-discharge phone calls assessing knowledge post-inter-
vention and correcting incorrect answers
Duration: not stated
Facilitator: pharmacist
Setting: hospital
Outcomes Warfarin knowledge
Self-efficacy
Country USA
Comparison Usual care
Length follow-up 12 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly assigned to the interven-
tion or usual care group after receiving patient ed-
ucation from the pharmacist. Authors do not de-
scribe the sequence generation
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Allocation concealment (selection bias) Low risk 66 patients were screened and offered participa-
tion in the study. There were 53 patients included
in the original randomised sample (80% of those
screened), with a low risk of inclusion bias. 42
of the original sample of 53 completed the study
(79%)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The authors do not state whether the personnel
delivering the intervention also treated the usual
care arm
Incomplete outcome data (attrition bias)
All outcomes
High risk The final sample included42 (79%) of the original
53 patients that were randomised to the study
Selective reporting (reporting bias) Low risk The authors describe two outcomes in their
method section (1) warfarin knowledge and (2)
self-efficacy. The authors report on both outcomes
in their results section. There was no published
protocol paper, thuswe cannot determine whether
those outcomes reported reflect those that were
included in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors do not state whether the researcher
or personnel were blinded to which arm the par-
ticipants were randomised to. However, we can
assume that participants and physicians were not
blinded to treatment allocation due to the nature
of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Authors do not state whether the person scoring
the questionnaires was blinded to the treatment
allocation
Thomson 2007
Methods Three/2-armed open, randomised controlled efficacy trial
Participants N randomised: 69 decision aid versus 67 guidelines
% AF: all AF patients
Demographics of cohort:
Age: 73.1±6.7 decision aid versus 73.7±6.2 guidelines
% female: 43.4 decision aid versus 44.6 guidelines
% white: not stated
% education above primary level: not stated
Inclusion/exclusion criteria: patients were recruited if theywere already taking warfarin
or if they were considering taking warfarin for the first time. Patients were eligible if they
aged 60 or over and had either chronic NVAF or PAF. Patients were excluded if they
were acute onset AF requiring cardioversion, previous stroke or TIA, contraindications
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for warfarin, taking warfarin for other indications, cognitive impairment, non-English
speaking, or at risk of cerebral bleed
Interventions Type: decision aid
Content: included individual risk and benefit presentation and a section to support
shared decision making
2 different decision aids
1. Used explicit value elicitation employing the standard gamble method and Markov
decision analysis “explicit tool”
2. Included only risk/benefit presentation “implicit tool” (computerised decision aid).
The doctor was trained to use the computerised decision aid
Early in the trial, the observation study (running alongside the trial) found the first
decision aid to be difficult, so this arm was discontinued (gamble method) and the
paper describes the results of the second arm versus evidence-based paper guidelines.
The intervention arm included benefits and harms of warfarin treatment, advantages
and disadvantages, personalised risk assessment (using the Framingham equation). The
presentation used graphical and numerical forms of presentation
Duration: mean 31 minutes long (range 16-41)
Facilitator: computerised tool
Setting: research clinic
Outcomes Decision conflict
Knowledge
State trait anxiety inventory
Degner’s decision making preference scale
Country Newcastle, UK
Comparison Guideline-based consultation
Length follow-up 3 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to either:
(a) computerised decision aid (interven-
tion) or (b) evidence-based paper guide-
lines (control), using electronically-gener-
ated random permuted blocks via a web-
based randomisation service provided by
the Centre for Health Services Research
Allocation concealment (selection bias) High risk 483 patients were eligible for the study, 145
patientswere eventually randomised (30%)
. Thus there is a substantial risk of inclusion
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bias
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The authors do not state whether those
physicians delivering the intervention also
treated the usual care arm
Incomplete outcome data (attrition bias)
All outcomes
Low risk 16 (23%) of the 69 patients allocated to
the decision aid tool did not receive the in-
tervention. 11 (16%) of the 67 patients al-
located to the guidelines group did not re-
ceive the intervention. In total 19% of pa-
tients randomised did not receive the inter-
vention. Reasons included withdrawal of
consent, death, illness, surgery, alcoholism,
and inability to use the tool
Selective reporting (reporting bias) Unclear risk The primary outcome was decision con-
flict. Secondary outcomes were state trait
anxiety, knowledge and decision mak-
ing preference. Decision conflict outcomes
were reported, but there was no tabulated
report of the scale breakdown. All of the
outcomes were reported, but mean scores
and numbers of patients per groupwere not
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors do not state whether the
researcher or personnel were blinded to
which arm the participants were ran-
domised to. However, we can assume
that participants and physicians were not
blinded to treatment allocation due to the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors do not state whether the per-
son scoring the questionnaires was blinded
to the treatment allocation
Voller 2005
Methods Prospective multicentre randomised controlled trial
Participants N randomised: 101 self-management versus 101 family doctor group
All NVAF patients
Demographics of cohort:
Age: 64.6±9.6 self-management versus 64.1±8.9 family doctor
% female: 28.6 self-management versus 38.6 family doctor
% white: not stated
% education above primary level: not stated
Inclusion/exclusion criteria: all patients whom long-term anticoagulation was indi-
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cated because of permanent non-valvular atrial fibrillation were to be included into the
investigation. Exclusion criteria were the lack of suitability for INR self-management,
participation in another study, alcohol or other addiction, a mechanical heart valve re-
placement or anticoagulant treatment already administered for another indication and
diseases such as AIDS or carcinomas. Patients with visual impairment were also excluded
Interventions Content: educational session following the standards of the working group for self
monitoring of anticoagulation ASA. Based on the intervention session developed my
Sawicki and colleagues (ref 12). The programme consisted of three consecutive weekly
teaching sessions for groups of 3 to 6 patients. Topics included anticoagulation in general,
INR self-monitoring, preventing bleeding, effects of diet and othermedication, reducing
or increasing dose, problems that may be encountered with operations, illness, exercise,
pregnancy etc
Duration: 60-90 minutes (based on Sawicki’s description)
Facilitator: not stated
Setting: not stated
Outcomes Primary endpoint:number of thromboembolic or hemorrhagic complications requiring
treatment
Secondary endpoints: the degree of handicap after stroke, the degree of severity of
haemorrhage, the proportion as well as cumulative time of the INR values in the indi-
vidual target range, INR variance, time course of complications and the cost efficiency
of self-measurement compared to conventional procedures
Country Germany
Comparison Family doctor group
Length follow-up Overall observation period (retrospective):
self-management 37.34±5.93 years
family doctor 40.25±6.07 years
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list developed before be-
ginning of the study with SAS-procedure
PROC PLAN
Allocation concealment (selection bias) Unclear risk Authors do not report how many partici-
pants were eligible for the study
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The authors do not state whether those
physicians delivering the intervention also
treated the usual care arm
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 202 patients were randomised to the study
and all of these patients were included in
the final analysis
Selective reporting (reporting bias) High risk The study was discontinued because the
number of cases was too small, and the
group comparisonwas confined to the eval-
uation of the number of INR values mea-
sured and the total period for which the pa-
tients remained outside, above and below
the target range
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors do not state whether the
researcher or personnel were blinded to
which arm the participants were ran-
domised to. However, we can assume
that participants and physicians were not
blinded to treatment allocation due to the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors do not state whether the per-
son scoring the questionnaires was blinded
to the treatment allocation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Armstrong 2011 Not an RCT
Bajorek 2005 Not an RCT, no control group
Baker 1991 Wrong patient group, no AF
Barcellona 2006 No unpublished AF data provided on request
Batty 2001 Does not measure any of the required outcomes
Blaise 2009 Not an RCT, retrospective study
Bloomfield 2011 Meta-analysis, not an RCT
Bump 1977 No AF patients
Burns 2009 Not an RCT, review paper
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Castelino 2010 Not an RCT
Chan 2006 No unpublished AF data provided on request
Christensen 2011 Limited education, specific to self-testing
Claes 2005 No AF patients
Claes 2006 No AF patients
Corbella 2009 Not an RCT
Cordasco 2009 No AF patients
Cromheecke 2000 No AF patients
Cromheecke 2001 No AF patients
Davis 2005 Not an RCT, survey
Dolor 2010 No education other than instruction to self-test
Duran-Parrondo 2011 Trial is not randomised
Field 2010 Training is for staff not patients
Fitzmaurice 1996 Not a patient intervention
Fitzmaurice 2000 Did not include an educational or behavioural intervention
Fitzmaurice 2005 No AF patients
Fraenkel 2011 Not compared to usual care, not an RCT
Gardiner 2006 No unpublished AF data provided on request
Gouin-Thibault 2010 Intervention for staff not patients
Grunau 2011 Patients were educated on self-monitoring only
Hasan 2011 Not an RCT
Holbrook 2007 No AF patients
Jackson 2004 Does not measure any of the required outcomes
Khan 2004 Randomisation procedure did not meet inclusion criteria
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Krause 2010 Systematic review not an RCT
Landefeld 1992 No AF patients
Leger 2004 Not an RCT, wrong patient group
Machtinger 2007 No unpublished AF data provided on request
Matchar 2005 No education or behaviour change within the intervention
Matchar 2010 Self-monitoring only, no educational or behavioural intervention
Mazor 2007 No AF patients
McCahon 2011 No breakdown of patient group
Megden 1999 Not an RCT
Menendez-Jandula 2005 No unpublished AF data provided on request
Nedaz 2002 Not an RCT, this paper is a commentary
Nilsson 2011 Abstract only, no mention of AF patients
Pernod 2008 No AF patients
Polzien 2007 Not an RCT, commentary
PRISM Study group 2003 Does not include any of the primary or secondary outcomes
Reverdin 2011 Not an RCT
Ryan 2009 No unpublished AF data provided on request
Saokaew 2010 Systematic review and meta-analysis, not an RCT
Satger 2009 Not an RCT, review article
Sawicki 1999 No unpublished AF data provided on request
Sawicki 2003 Not an RCT, no comparison group
Siebenhofer 2007 No unpublished AF data provided on request
Stone 1989 No unpublished AF data provided on request
Sunderji 2005 Education only relates to self-monitoring
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Taylor 1997 Not an RCT
Trivalle 2010 Education of staff not patients
Tuiskula 2011 Not an RCT
Vadher 1996 No breakdown of patient group
Vadher 1997 No breakdown of patient group
Waterman 2001 No AF patients, no comparison group
Waterman 2001 b No patient intervention
Watzke 2000 No unpublished AF data provided on request
Winans 2010 Not an RCT
Witt 2005 Not an RCT, retrospective, observational cohort study
Woodend 2005 Not an RCT (commentary)
Wurster 2006 Not an RCT
Characteristics of ongoing studies [ordered by study ID]
Hua 2011
Trial name or title Practice nurse-based, individual and video-assisted patient education in oral anticoagulation - Protocol of a
cluster-randomized controlled trial (No trial acronym)
Methods Cluster randomised controlled trial of 22 GP practices
Participants All patients taking OAT (with a range of indications)
Interventions Educational intervention including a video, brochure and individual training session versus usual care
Outcomes Primary outcome: number of correctly answered questions from the 13-item OAT questionnaire
Secondary outcomes: time spent in therapeutic range, subjective feelings of safety and complications related
to OAT
Starting date January 2011
Contact information thanhduchua@med.uni-goettingen.de
Notes
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Smith 2010
Trial name or title TRial of an Educational intervention on patients’ knowledge of Atrial fibrillation and anticoagulant therapy,
INR control, and outcome of Treatment with warfarin (TREAT)
Methods Randomised controlled trial
Participants Newly diagnosed AF patients
Interventions One-off one-hour educational intervention, with DVD, consultation, worksheet and booklet
Outcomes TTR, knowledge, illness perceptions, beliefs about medication, cost-effectiveness, hospital anxiety and de-
pression, quality of life, stroke, thromboembolic events, major and minor bleeding
Starting date December 2010
Contact information d.a.lane@bham.ac.uk
Notes
Stafford 2011
Trial name or title A role for pharmacists in community-based post-discharge warfarin management: protocol for the ’the role
of community pharmacy in post hospital management of patients initiated on wafarin’ study (No acronym)
Methods Prospective controlled cohort study
Participants All patients discharged from hospital on warfarin
Interventions Post-discharge warfarin management service, visits involve a home medicines review, warfarin education,
provision of resources dependent on patients understanding and INR monitoring
Outcomes Primary outcome: proportion of patients experiencing a major bleeding event in the 90 days after hospital
discharge
Secondary outcomes: INR control (TTR), warfarin-related adverse events, warfarin knowledge, QoL, adher-
ence
Starting date 2011
Contact information leanne.stafford@utas.edu.au
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Time in therapeutic INR range
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time in therapeutic INR range 2 69 Mean Difference (IV, Random, 95% CI) 6.31 [-5.63, 18.25]
Comparison 2. Decision conflict
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Decision conflict 2 721 Mean Difference (IV, Random, 95% CI) -0.10 [-0.17, -0.02]
Analysis 1.1. Comparison 1 Time in therapeutic INR range, Outcome 1 Time in therapeutic INR range.
Review: Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Comparison: 1 Time in therapeutic INR range
Outcome: 1 Time in therapeutic INR range
Study or subgroup Self monitoring Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Christensen 2007 11 77.3 (11.59) 9 67.96 (23.52) 50.3 % 9.34 [ -7.48, 26.16 ]
Gadisseur 2003 6 70.32 (18.73) 43 67.08 (26.43) 49.7 % 3.24 [ -13.70, 20.18 ]
Total (95% CI) 17 52 100.0 % 6.31 [ -5.63, 18.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours usual care Favours self monitoring
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Analysis 2.1. Comparison 2 Decision conflict, Outcome 1 Decision conflict.
Review: Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Comparison: 2 Decision conflict
Outcome: 1 Decision conflict
Study or subgroup Decision aid Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Man-Son-Hing 1999 139 1.65 (0.45) 148 1.74 (0.54) 40.2 % -0.09 [ -0.20, 0.02 ]
McAlister 2005 219 1.6 (0.5) 215 1.7 (0.5) 59.8 % -0.10 [ -0.19, -0.01 ]
Total (95% CI) 358 363 100.0 % -0.10 [ -0.17, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours usual care Favours decision aid
A P P E N D I C E S
Appendix 1. Search strategy
The Cochrane Library
#1 MeSH descriptor patient education as topic this term only
#2 MeSH descriptor attitude to health explode all trees
#3 MeSH descriptor patient participation this term only
#4 MeSH descriptor behavior therapy this term only
#5 MeSH descriptor cognitive therapy this term only
#6 MeSH descriptor counseling explode all trees
#7 MeSH descriptor motivation this term only
#8 MeSH descriptor goals this term only
#9 MeSH descriptor Biofeedback (Psychology) this term only
#10 MeSH descriptor decision support techniques this term only
#11 MeSH descriptor Communications Media explode all trees
#12 education in All Text
#13 (training in All Text or train in All Text)
#14 (teaching in All Text or teach in All Text)
#15 (behaviour* in All Text or behavior* in All Text)
#16 “patient knowledge” in All Text
#17 counsel* in All Text
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#18 (cognitiv* in All Text near/3 therapy in All Text)
#19 (cognitiv* in All Text near/3 intervention* in All Text)
#20 motivation* in All Text
#21 contingency next management in All Text
#22 (biofeedback in All Text or bio-feedback in All Text)
#23 (goal in All Text or goals in All Text)
#24 (decision* in All Text near/3 aid* in All Text)
#25 pamphlet* in All Text
#26 booklet* in All Text
#27 video* in All Text
#28 decision next aid* in All Text
#29 “patient participation” in All Text
#30 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10)
#31 (#11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20)
#32 (#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29)
#33 (#30 or #31 or #32)
#34 MeSH descriptor warfarin this term only
#35 MeSH descriptor Coumarins explode all trees
#36 MeSH descriptor anticoagulants this term only
#37 MeSH descriptor vitamin k explode all trees with qualifiers: AI
#38 oral next anticoagula* in All Text
#39 Oral next anti-coagula* in All Text
#40 (“vitamin K” in All Text and (antagonist* in All Text or inhibitor* in All Text) )
#41 “antivitamin K” in All Text
#42 “anti-vitamin K” in All Text
#43 warfarin in All Text
#44 acenocoumarol in All Text
#45 sintrom in All Text
#46 sinthrome in All Text
#47 jantoven in All Text
#48 marevan in All Text
#49 coumadin* in All Text
#50 waran in All Text
#51 phenprocoumon in All Text
#52 nicoumalone in All Text
#53 VKA in All Text
#54 coumarin* in All Text
#55 dicoumarol in All Text
#56 dicumarol in All Text
#57 (#34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43)
#58 (#44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56)
#59 (#57 or #58)
#60 (#33 and #59)
MEDLINE on Ovid
1. Warfarin/
2. acenocoumarol/
3. Coumarins/
4. Phenindione/
5. Dicumarol/
6. Anticoagulants/
7. oral anticoagula$.tw.
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8. exp Vitamin K/ai [Antagonists & Inhibitors]
9. warfarin.tw.
10. acenocoumarol.tw.
11. sintrom.tw.
12. sinthrome.tw.
13. jantoven.tw.
14. marevan.tw.
15. coumadin$.tw.
16. waran.tw.
17. Phenprocoumon/
18. nicoumalone.tw.
19. (vitamin k adj3 antagonist$).tw.
20. vitamin k inhibitor$.tw.
21. oral anticoagula$.tw.
22. oral anti-coagula$.tw.
23. vka.tw.
24. antivitamin k.tw.
25. anti-vitamin k.tw.
26. or/1-25
27. Patient Education as Topic/
28. exp Attitude to Health/
29. Patient Participation/
30. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw.
31. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw.
32. patient knowledge.tw.
33. Behavior Therapy/
34. Cognitive Therapy/
35. exp counseling/
36. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw.
37. (cogniti$ adj3 (therap$ or intervention$)).tw.
38. counsel$.tw.
39. Motivation/
40. motivational interview$.tw.
41. contingency management.tw.
42. biofeedback.tw.
43. bio-feedback.tw.
44. goals/
45. (goal$ adj3 set$).tw.
46. decision support techniques/
47. decision$ aid$.tw.
48. exp communications media/
49. pamphlet$.tw.
50. booklet$.tw.
51. video$.tw.
52. or/27-51
53. 26 and 52
54. randomized controlled trial.pt.
55. controlled clinical trial.pt.
56. randomized.ab.
57. placebo.ab.
58. clinical trials as topic.sh.
59. randomly.ab.
60. trial.ti.
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61. 54 or 55 or 56 or 57 or 58 or 59 or 60
62. exp animals/ not humans.sh.
63. 61 not 62
64. 53 and 63
EMBASE Ovid
RCT filter as recommended in the Cochrane Handbook (Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In:
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009).
The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.) applied.
1. phenindione/
2. antivitamin K/
3. exp coumarin anticoagulant/
4. anticoagulant agent/
5. warfarin.tw.
6. acenocoumarol.tw.
7. sintrom.tw.
8. sinthrome.tw.
9. jantoven.tw.
10. marevan.tw.
11. coumadin$.tw.
12. waran.tw.
13. nicoumalone.tw.
14. (vitamin k adj3 antagonist$).tw.
15. vitamin k inhibitor$.tw.
16. oral anticoagula$.tw.
17. oral anti-coagula$.tw.
18. vka*.tw.
19. antivitamin k.tw.
20. anti-vitamin k.tw.
21. coumarin$.tw.
22. vitamin K group/po [Oral Drug Administration]
23. or/1-22
24. patient education/
25. attitude to health/
26. patient participation/
27. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw.
28. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw.
29. patient knowledge.tw.
30. behavior therapy/
31. cognitive therapy/
32. exp counseling/
33. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw.
34. (cogniti$ adj3 (therap$ or intervention$)).tw.
35. counsel$.tw.
36. motivation/
37. motivational interview$.tw.
38. contingency management.tw.
39. biofeedback.tw.
40. bio-feedback.tw.
41. (goal$ adj3 set$).tw.
42. decision support system/
43. decision$ aid$.tw.
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44. (decision$ adj3 support).tw.
45. mass medium/
46. pamphlet$.tw.
47. booklet$.tw.
48. video$.tw.
49. or/24-48
50. random$.tw.
51. factorial$.tw.
52. crossover$.tw.
53. cross over$.tw.
54. cross-over$.tw.
55. placebo$.tw.
56. (doubl$ adj blind$).tw.
57. (singl$ adj blind$).tw.
58. assign$.tw.
59. allocat$.tw.
60. volunteer$.tw.
61. crossover procedure/
62. double blind procedure/
63. randomized controlled trial/
64. single blind procedure/
65. or/50-64
66. (animal/ or nonhuman/) not human/
67. 65 not 66
68. 23 and 49 and 67
PsycINFO
1. anticoagulant drugs/
2. warfarin.tw.
3. acenocoumarol.tw.
4. coumadin$.tw.
5. waran.tw.
6. nicoumalone.tw.
7. (vitamin k adj3 antagonist$).tw.
8. oral anticoagula$.tw.
9. vka*.tw.
10. coumarin$.tw.
11. or/1-10
12. client education/
13. client participation/
14. behavior therapy/
15. cognitive therapy/
16. exp counseling/
17. motivation/
18. exp goals/
19. biofeedback/
20. decision making/
21. exp communications media/
22. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw.
23. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw.
24. patient knowledge.tw.
25. health knowledge/
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26. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw.
27. (cogniti$ adj3 (therap$ or intervention$)).tw.
28. health attitudes/
29. counsel$.tw.
30. motivational interview$.tw.
31. contingency management.tw.
32. biofeedback.tw.
33. bio-feedback.tw.
34. (goal$ adj3 set$).tw.
35. decision$ aid$.tw.
36. (decision$ adj3 support).tw.
37. pamphlet$.tw.
38. booklet$.tw.
39. video$.tw.
40. or/12-39
41. 11 and 40
42. random$.tw.
43. factorial$.tw.
44. crossover$.tw.
45. cross-over$.tw.
46. placebo$.tw.
47. (doubl$ adj blind$).tw.
48. (singl$ adj blind$).tw.
49. assign$.tw.
50. allocat$.tw.
51. volunteer$.tw.
52. control*.tw.
53. “2000”.md.
54. or/42-53
55. 41 and 54
CINAHL
as run on 9 August 2012:
S72 S52 and S71
S71 S53 or S54 or S55 or S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 Limiters
- Published Date from: 20100501-20120931
S70 S53 or S54 or S55 or S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69
S69 cross-over*
S68 crossover*
S67 volunteer*
S66 (MH “Crossover Design”)
S65 allocat*
S64 control*
S63 assign*
S62 placebo*
S61 (MH “Placebos”)
S60 random*
S59 (doubl* N1 mask*)
S58 (singl* N1 mask*)
S57 (doubl* N1 blind*)
S56 (singl* N1 blind)
S55 (clinic* N1 trial?)
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S54 PT clinical trial
S53 (MH “Clinical Trials”)
S52 S25 and S51
S51 S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43
or S44 or S45 or S46 or S47 or S48 or S49 or S50
S50 video*
S49 booklet*
S48 pamphlet*
S47 (MH “Communications Media”)
S46 (decision* aid*)
S45 (MH “Decision Support Techniques”)
S44 (goal* N3 set*)
S43 (MH “Goals and Objectives”)
S42 bio-feedback
S41 biofeedback
S40 contingency management
S39 motivational interview*
S38 (MH “Motivation”)
S37 counsel*
S36 (cogniti* N3 (therap* or intervention*))
S35 (behavi* N3 (therap* or manage* or modif* or chang* or intervention*))
S34 (MH “Counseling”)
S33 (MH “Cognitive Therapy”)
S32 (MH “Behavior Therapy”)
S31 patient knowledge
S30 (patient* N3 (train* or teach* or educat* or inform*))
S29 ((educat* or train* or teach*) N3 (program* or intervention*))
S28 (MH “Consumer Participation”)
S27 (MH “Attitude to Health”)
S26 (MH “Patient Education”)
S25 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
or S21 or S22 or S23 or S24
S24 anti-vitamin k
S23 antivitamin k
S22 vka*
S21 oral anti-coagula*
S20 oral anticoagula*
S19 vitamin k inhibitor*
S18 (vitamin k N3 antagonist*)
S17 nicoumalone
S16 “Phenprocoumon”
S15 waran
S14 coumadin*
S13 marevan
S12 jantoven
S11 sinthrome
S10 sintrom
S9 warfarin
S8 (MH “Vitamin K”)
S7 oral anticoagula*
S6 (MH “Anticoagulants”)
S5 “Dicumarol”
S4 “Phenindione”
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S3 “Coumarins”
S2 “acenocoumarol”
S1 (MH “Warfarin”)
as run on 21 June 2010:
S76 S57 and S75
S75 S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 or S70 or S71 or S72 or S73 or S74
S74 TX cross-over*
S73 TX crossover*
S72 TX volunteer*
S71 (MH “Crossover Design”)
S70 TX allocat*
S69 TX control*
S68 TX assign*
S67 TX placebo*
S66 (MH “Placebos”)
S65 TX random*
S64 TX (doubl* N1 mask*)
S63 TX (singl* N1 mask*)
S62 TX (doubl* N1 blind*)
S61 TX (singl* N1 blind*)
S60 TX (clinic* N1 trial?)
S59 PT clinical trial
S58 (MH “Clinical Trials+”)
S57 S17 and S56
S56 S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35
or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51 or S52 or S53 or
S54 or S55
S55 (TI video*) or (AB video*)
S54 (TI booklet*) or (AB booklet*)
S53 (TI pamphlet*) or (AB pamphlet*)
S52 (MH “Communications Media+”)
S51 (TI decision* N3 support) or (AB decision* N3 support)
S50 (TI “decision* aid*”) or (AB “decision* aid*”)
S49 (MH “Decision Support Techniques+”)
S48 (TI goal* N3 set*) or (AB goal* N3 set*)
S47 (TI bio-feedback) or (AB bio-feedback)
S46 (TI biofeedback) or (AB biofeedback)
S45 (TI “contingency management”) or (AB “contingency management”)
S44 (TI “motivational interview*”) or (AB “motivational interview*”)
S43 (MH “Motivation+”)
S42 (TI counsel*) or (AB counsel*)
S41 (TI cogniti* N3 intervention*) or (AB cogniti* N3 intervention*)
S40 (TI cogniti* N3 therap*) or (AB cogniti* N3 therap*)
S39 (TI behavi* N3 intervention*) or (AB behavi* N3 intervention*)
S38 (TI behavi* N3 chang*) or (AB behavi* N3 chang*)
S37 (TI behavi* N3 modif*) or (AB behavi* N3 modif*)
S36 (TI behavi* N3 manage*) or (AB behavi* N3 manage*)
S35 (TI behavi* N3 therap*) or (AB behavi* N3 therap*)
S34 (MH “Counseling+”)
S33 (MH “Cognitive Therapy”)
S32 (MH “Behavior Therapy”)
S31 (TI “patient knowledge”) or (AB “patient knowledge”)
S30 (TI patient* N3 inform*) or (AB patient* N3 inform*)
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S29 (TI patient* N3 educat*) or (AB patient* N3 educat*)
S28 (TI patient* N3 teach*) or (AB patient* N3 teach*)
S27 (TI patient* N3 train*) or (AB patient* N3 train*)
S26 (TI teach* N3 intervention*) or (AB teach* N3 intervention*)
S25 (TI teach* N3 program*) or (AB teach* N3 program*)
S24 (TI train* N3 intervention*) or (AB train* N3 intervention*)
S23 (TI train* N3 program*) or (AB train* N3 program*)
S22 (TI educat* N3 intervention*) or (AB educat* N3 intervention*)
S21 (TI educat* N3 program*) or (AB educat* N3 program*)
S20 (MH “Consumer Participation”)
S19 (MH “Attitude to Health”)
S18 (MH “Patient Education”)
S17 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16
S16 (TI dicumarol) or (AB dicumarol)
S15 (TI dicoumarol) or (AB dicoumarol)
S14 (TI coumarin*) or (AB coumarin*)
S13 (TI VKA*) or (AB VKA*)
S12 (TI phenprocoumon) or (AB phenprocoumon)
S11 (TI coumadin*) or (AB coumadin*)
S10 (TI sintrom) or (AB sintrom)
S9 (TI acenocoumarol) or (AB acenocoumarol)
S8 (TI warfarin) or (AB warfarin)
S7 (TI “antivitamin K”) or (AB “antivitamin K”)
S6 (TI “vitamin K” N2 inhibitor*) or (AB “vitamin K” N2 inhibitor*)
S5 (TI “vitamin K” N2 antagonist*) or (AB “vitamin K” N2 antagonist*)
S4 (TI oral N2 anti-coagula*) or (AB oral N2 anti-coagula*)
S3 (TI oral N2 anticoagula*) or (AB oral N2 anticoagula*)
S2 (MH “Warfarin”)
S1 (MH “Anticoagulants”)
C O N T R I B U T I O N S O F A U T H O R S
Data collection, paper searches, screening and appraisal, and data extraction were conducted by Drs Clarkesmith and Lane. Dr
Clarkesmith wrote the initial draft of the Introduction andMethods of the review paper, which were edited byDr Lane. Drs Clarkesmith
and Lane performed the data analysis together and drafted the Results and Discussion sections. Both Dr Clarkesmith and Dr Lane
revised and commented on subsequent drafts. Professor Pattison contributed to the interpretation of the analyses and provided critical
revision of drafts of the review.
D E C L A R A T I O N S O F I N T E R E S T
DrClarkesmith has completed a PhD studentship that was funded by an Investigator-Initiated Educational Grant fromBayerHealthcare
andAstonUniversity, but currently works as a post-doctoral researcher.Dr Lane is the principal grant holder for TREAT.DrClarkesmith
is currently the primary investigator for the ’TRial of an Educational intervention on patients’ knowledge of Atrial fibrillation and
anticoagulant therapy, INR control, and outcome of Treatment with warfarin’ (TREAT). The trial protocol manuscript has been
published in BMC Cardiovascular Disorders (Smith 2010) and the results will be published later this year. Dr Lane and Professor
Pattison were the educational supervisors of Dr Clarkesmith for the TREAT study. This review is not funded by Bayer Healthcare.
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• New Source of support, Not specified.
This review is funded by University of Birmingham Centre for Cardiovascular Sciences, City Hospital and Aston University. Bayer
Healthcare are not funding this review, but are providing support to DS who is one author of the review.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. Contributions of the authors
The contributions of authors has changed from the original protocol (see contributions of authors section).
2. Decision conflict as a secondary outcome
Decision conflict was included as a secondary outcome in the final analysis. Whilst not specified as an outcome of interest in the original
protocol, it was highlighted as a common secondary outcome measure in three of the studies included in the final review. For this
reason, the authors decided to include these data within the results.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗International Normalized Ratio [standards]; ∗Patient Education as Topic; Administration, Oral; Anticoagulants [∗administration &
dosage; adverse effects]; Atrial Fibrillation [blood; ∗complications]; Chronic Disease; Decision Support Techniques; Drug Monitoring
[∗methods; standards]; Medication Adherence; Randomized Controlled Trials as Topic; Self Care [methods]; Stroke [blood; etiology;
∗prevention & control]
MeSH check words
Aged; Humans; Middle Aged
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